PDL Biopharma (PDLI) 10-Q 12 May 14 2014 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2014	Apr. 29, 2014
DocumentAndEntityInformation [Abstract]	'	'
Entity Registrant Name	'PDL BIOPHARMA, INC.	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	160,594,818
Amendment Flag	'false	'
Entity Central Index Key	'0000882104	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Well-known Seasoned Issuer	'Yes	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Revenues	'	'
Royalties	$139,664	$91,847
Total revenues	139,664	91,847
Operating expenses	'	'
Cost of royalty revenue (amortization of intangible assets)	11,931	0
General and administrative	4,582	7,186
Operating Expenses	16,513	7,186
Operating income	123,151	84,661
Non-operating expense, net	'	'
Interest and other income, net	9,121	3,838
Interest expense	-10,525	-6,000
Losses on Extinguishment of Debt	-6,143	0
Total non-operating expense, net	-7,547	-2,162
Income before income taxes	115,604	82,499
Income tax expense	42,721	29,028
Net income	$72,883	$53,471
Net income per share	'	'
Basic (in Dollars per Share)	$0.48	$0.38
Diluted (in Dollars per Share)	$0.44	$0.36
Weighted average shares outstanding	'	'
Basic (in Shares)	151,198	139,816
Diluted (in Shares)	164,571	149,101
Cash dividends declared per common share (in Dollars per Share)	$0.60	$0.60

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014		Mar. 31, 2013
Statement of Comprehensive Income [Abstract]	'		'
Net income	$72,883		$53,471
Other comprehensive income (loss), net of tax	'		'
Change in fair value of investments in available-for-sale securities, net of tax	-1,092		-3
Adjustment for net (gains) losses realized and included in net income, net of tax	0		0
Total change in unrealized gains (losses) on investments in available-for-sale securities, net of tax	-1,092	[1]	-3	[1]
Unrealized gains (losses) on cash flow hedges	67		3,567
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax	728		1,247
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax	795	[2]	4,814	[2]
Total other comprehensive income (loss), net of tax	-297		4,811
Comprehensive income	$72,586		$58,282
[1]	Net of tax of ($588) and ($2) for the three months ended March 31, 2014 and 2013, respectively.
[2]	Net of tax of $428 and $2,592 for the three months ended March 31, 2014 and 2013, respectively.

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parentheticals) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Statement of Comprehensive Income [Abstract]	'	'
Unrealized gains (losses) on available-for-sale securities, tax	($588)	($2)
Unrealized gains (losses) on cash flow hedges, tax	$428	$2,592

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2014		Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'		'
Cash and cash equivalents	$334,035	[1]	$94,302	[2]
Short-term investments	3,558	[1]	5,238	[2]
Receivables from licensees and other	11,650	[1]	300	[2]
Deferred tax assets	2,053	[1]	377	[2]
Notes receivable	1,200	[1]	1,208	[2]
Prepaid and other current assets	3,104	[1]	6,272	[2]
Total current assets	355,600	[1]	107,697	[2]
Property and equipment, net	35	[1]	41	[2]
Notes and other receivables, long-term	247,200	[1]	193,840	[2]
Long-term deferred tax assets	17,369	[1]	6,700	[2]
Other assets	8,629	[1]	0	[2]
Intangible Assets, Net (Excluding Goodwill)	223,746	[1]	235,677	[1]
Total assets	852,579	[1]	543,955	[2]
Current liabilities:	'		'
Accounts payable	410	[1]	287	[2]
Accrued liabilities	87,030	[1]	11,857	[2]
Accrued Income Taxes, Current	5,335	[1]	0	[2]
Term loan payable	55,921	[1]	74,397	[1]
Convertible Notes Payable, Current	196,275	[1]	320,883	[2]
Total current liabilities	344,971	[1]	407,424	[2]
Convertible notes payable	270,944	[1]	0	[2]
Other long-term liabilities	34,450	[1]	23,042	[2]
Total liabilities	650,365	[1]	430,466	[2]
Commitments and contingencies (Note 9)	'	[1]	'	[2]
Stockholders' deficit:	'		'
Preferred stock, par value $0.01 per share, 10,000 shares authorized; no shares issued and outstanding	0	[1]	0	[2]
Common stock, par value $0.01 per share, 350,000 shares authorized; 160,228 and 139,935 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively	1,602	[1]	1,399	[2]
Additional paid-in capital	-121,011	[1]	-233,173	[2]
Accumulated other comprehensive loss	-5,185	[1]	-4,888	[2]
Retained earnings	326,808	[1]	350,151	[2]
Total stockholders' equity	202,214	[1]	113,489	[2]
Total liabilities and stockholders' equity	$852,579	[1]	$543,955	[2]
[1]	unaudited
[2]	Note 1

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) (USD $)	Mar. 31, 2014		Dec. 31, 2013
In Thousands, except Per Share data, unless otherwise specified
Statement of Financial Position [Abstract]	'		'
Preferred stock par value (in Dollars per Share)	$0.01	[1]	$0.01	[2]
Preferred stock, shares authorized (in Shares)	10,000	[1]	10,000	[2]
Preferred stock, shares issued (in Shares)	0	[1]	0	[2]
Preferred stock, shares outstanding (in Shares)	0	[1]	0	[2]
Common stock par value (in Dollars per Share)	$0.01	[1]	$0.01	[2]
Common stock, shares authorized (in Shares)	350,000	[1]	350,000	[2]
Common stock, shares issued (in Shares)	160,228	[1]	139,935	[2]
Common stock, shares outstanding (in Shares)	160,228	[1]	139,935	[2]
[1]	unaudited
[2]	Note 1

CONDENSED_CONSOLIDATED_STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014		Mar. 31, 2013
Other Significant Noncash Transaction, Value of Consideration Given	$157,591		$0
Cash flows from operating activities	'		'
Net income	72,883		53,471
Adjustments to reconcile net income to net cash provided by operating activities:	'		'
Amortization of convertible notes and term loan offering costs	4,817		3,251
Amortization of Intangible Assets	11,931		0
Losses on Extinguishment of Debt	-6,143		0
Depreciation, Amortization and Accretion, Net	-45		50
Hedge ineffectiveness on foreign exchange contracts	-2		-3
Stock-based compensation expense	194		156
Deferred income taxes	-1,012		-276
Changes in assets and liabilities:	'		'
Receivables from licensees and other	-11,350		216
Prepaid and other current assets	844		-479
Accrued interest on notes receivable	-3,284		-2,490
Other assets	0		0
Accounts payable	123		-570
Accrued liabilities	2,682		-669
Increase (Decrease) in Income Taxes Payable	5,335		0
Other long-term liabilities	2,520		198
Net cash provided by operating activities	91,779		52,855
Cash flows from investing activities	'		'
Maturities of investments	0		12,405
Issuance of notes receivable	-50,000		-2,579
Repayment of notes receivable	0		9,279
Net cash provided by/(used in) investing activities	-50,000		19,105
Cash flows from financing activities	'		'
Repurchase of Convertible Notes	29,906		0
Proceeds from the issuance of Convertible Notes, net	300,000		0
Payment of debt issuance costs	-9,824		0
Purchase of purchased call options, net of tax	-30,951		0
Proceeds from Issuance of Warrants	11,427		0
Repayments of Notes Payable	-18,750		0
Cash dividends paid	-24,042		-20,980
Net cash provided by/(used in) financing activities	197,954		-20,980
Net increase in cash and cash equivalents	239,733		50,980
Cash and cash equivalents at beginning of the period	94,302	[1]	131,212
Cash and cash equivalents at end of period	334,035	[2]	182,192
Supplemental cash flow information	'		'
Cash paid for income taxes	34,000		28,000
Cash paid for interest (including convertible debt inducement)	$5,454		$2,588
[1]	Note 1
[2]	unaudited

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	1. Summary of Significant Accounting Policies
	Basis of Presentation
	The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with GAAP for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that management of PDL believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.
	The accompanying Condensed Consolidated Financial Statements and related financial information should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December 31, 2013, included in our Annual Report on Form 10-K filed with the SEC. The Condensed Consolidated Balance Sheet at December 31, 2013, has been derived from the audited Consolidated Financial Statements at that date.
	Principles of Consolidation
	The Condensed Consolidated Financial Statements include the accounts of PDL and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation. Our condensed consolidated financial statements are prepared in accordance with GAAP and the rules and regulations of the SEC.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
	Notes Receivable and Other Long-Term Receivables
	We account for our notes receivable at amortized cost, net of unamortized origination fees, if any. Related fees and costs are recorded net of any amounts reimbursed. Interest is accreted or accrued to interest income using the interest method.
	Customer Concentration
	The percentage of total revenue recognized, which individually accounted for ten percent or more of our total revenues, was as follows:
			Three Months Ended March 31,
	Licensee	Product Name	2014		2013
	Genentech	Avastin®	29	%	36	%
		Herceptin®	27	%	33	%
		Lucentis®	12	%	13	%
	Biogen Idec1	Tysabri®	9	%	14	%
	Depomed	Glumetza®	17	%	0	%
	______________________
	1 In April 2013, Biogen Idec completed its purchase of Elan's interest in Tysabri. Prior to this our licensee for Tysabri was identified as Elan.
	Foreign Currency Hedging
	We enter into foreign currency hedges to manage exposures arising in the normal course of business and not for speculative purposes.
	We hedge certain Euro-denominated currency exposures related to royalties associated with our licensees’ product sales with Euro forward contracts. In general, these contracts are intended to offset the underlying Euro market risk in our royalty revenues. These contracts currently extend through the fourth quarter of 2014. We designate foreign currency exchange contracts used to hedge royalty revenues based on underlying Euro-denominated licensee product sales as cash flow hedges.
	At the inception of each hedging relationship and on a quarterly basis, we assess hedge effectiveness. The fair value of the Euro contracts is estimated using pricing models with readily observable inputs from actively quoted markets and is disclosed on a gross basis. The aggregate unrealized gain or loss, net of tax, on the effective component of the hedge is recorded in stockholders’ equity as accumulated other comprehensive income (loss). Gains or losses on cash flow hedges are recognized as an adjustment to royalty revenue in the same period that the hedged transaction impacts earnings as royalty revenue. Any gain or loss on the ineffective portion of our hedge contracts is reported in interests and other income, net in the period the ineffectiveness occurs.

Net_Income_per_Share

Net Income per Share	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Net Income per Share	'
	2. Net Income per Share
		Three Months Ended
		March 31,
	Net Income per Basic and Diluted Share:	2014		2013
	(in thousands except per share amounts)
	Numerator
	Net income used to compute net income per basic share	$	72,883	$	53,471
	Add back interest expense for convertible notes, net of estimated tax of approximately $0 and $3 for the three months ended March 31, 2014 and 2013, respectively	—		6
	Net income used to compute net income per diluted share	$	72,883	$	53,477
	Denominator
	Weighted-average shares used to compute net income per basic share	151,198		139,816
	Restricted stock outstanding	68		61
	Effect of dilutive stock options	21		18
	Assumed conversion of Series 2012 Notes	6,903		6,688
	Assumed conversion of May 2015 Notes	6,381		2,345
	Assumed conversion of February 2015 Notes	—		173
	Weighted-average shares used to compute net income per diluted share	164,571		149,101
	Net income per basic share	$	0.48	$	0.38
	Net income per diluted share	$	0.44	$	0.36
	We compute net income per diluted share using the sum of the weighted-average number of common and common equivalents shares outstanding. Common equivalent shares used in the computation of net income per diluted share include shares that may be issued under our stock options and restricted stock awards, our February 2018 Notes, our Series 2012 Notes and our May 2015 Notes on a weighted average basis for the period that the notes were outstanding, including the effect of adding back interest expense and the underlying shares using the if converted method. In the first quarter of 2012, $179.0 million aggregate principal of our February 2015 Notes was exchanged for our Series 2012 Notes, in the third quarter of 2013, $1.0 million aggregate principal of our February 2015 Notes was exchanged for our Series 2012 Notes, and the February 2015 Notes were retired, and in the first quarter of 2014, $131.7 million aggregate principal of our Series 2012 Notes was retired in a privately negotiated exchange and purchase agreements.
	In May 2011, we issued our May 2015 Notes, in January and February 2012, we issued our Series 2012 Notes, and in February 2014, we issued our February 2018 Notes. The February 2018 Notes, Series 2012 Notes and May 2015 Notes are net share settled, with the principal amount settled in cash and the excess settled in our common stock. The weighted average share adjustments related to our February 2018 Notes, Series 2012 Notes and May 2015 Notes, shown in the table above, include the shares issuable in respect of such excess.
	May 2015 Notes Purchase Call Option and Warrant Potential Dilution
	We excluded from our calculations of net income per diluted share 21.5 million and 20.0 million shares for the three months ended March 31, 2014 and 2013, respectively, for warrants issued in 2011, because conversion of the underlying May 2015 Notes is not assumed. These securities could be dilutive in future periods. Our purchased call options, issued in 2011, will always be anti-dilutive and therefore 25.3 million and 23.5 million shares were excluded from our calculations of net income per diluted share for the three months ended March 31, 2014 and 2013, respectively, because they have no effect on diluted net income per share. For information related to the conversion rates on our convertible debt, see Note 10.
	February 2018 Notes Purchase Call Option and Warrant Potential Dilution
	We excluded from our calculation of net income per diluted share 29.0 million shares for the three months ended March 31, 2014 for warrants issued in February 2014, because the exercise price of the warrants exceeded the VWAP of our common stock and conversion of the underlying February 2018 Notes is not assumed, no stock would be issuable upon conversion. These securities could be dilutive in future periods. Our purchased call options, issued in February 2014, will always be anti-dilutive and therefore 32.7 million shares were excluded from our calculation of net income per diluted share for the three months ended March 31, 2014, because they have no effect on diluted net income per share. For information related to the conversion rates on our convertible debt, see Note 10.
	Anti-Dilutive Effect of Stock Options and Restricted Stock Awards
	For the three months ended March 31, 2014, we excluded approximately 115,000 shares underlying outstanding stock options calculated on a weighted average basis, from our net income per diluted share calculations because their effect was anti-dilutive.
	For the three months ended March 31, 2013, we excluded approximately 139,000 and 20,000 shares underlying outstanding stock options and restricted stock awards, respectively, calculated on a weighted average basis, from our net income per diluted share calculations because their effect was anti-dilutive.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	3. Fair Value Measurements
	The fair value of our financial instruments are estimates of the amounts that would be received if we were to sell an asset or pay to transfer a liability in an orderly transaction between market participants at the measurement date or exit price. The assets and liabilities are categorized and disclosed in one of the following three categories:
	Level 1 – based on quoted market prices in active markets for identical assets and liabilities;
	Level 2 – based on quoted market prices for similar assets and liabilities, using observable market based inputs or unobservable market based inputs corroborated by market data; and
	Level 3 – based on unobservable inputs using management’s best estimate and assumptions when inputs are unavailable.
	The following tables present the fair value of our financial instruments measured at fair value on a recurring basis by level within the valuation hierarchy.
		March 31, 2014						December 31, 2013
		Level 1		Level 2		Total		Level 1		Level 2		Total
	(In thousands)
	Financial assets:
	Money market funds	$	165,051	$	—	$	165,051	$	85,970	$	—	$	85,970
	Corporate securities	—		3,558		3,558		—		5,238		5,238
	Total	$	165,051	$	3,558	$	168,609	$	85,970	$	5,238	$	91,208
	Financial liabilities:
	Foreign currency hedge contracts	$	—	$	7,646	$	7,646	$	—	$	8,871	$	8,871
	Corporate securities consist primarily of U.S. corporate equity holdings. The fair value of corporate securities is estimated using recently executed transactions or market quoted prices, where observable. Independent pricing sources are also used for valuation.
	The fair value of the foreign currency hedge contracts is estimated based on pricing models using readily observable inputs from actively quoted markets and are disclosed on a gross basis.
	There have been no transfers between levels during the three months ended March 31, 2014, and December 31, 2013. The Company recognizes transfers between levels on the date of the event or change in circumstances that caused the transfer.
	The following tables present the fair value of assets and liabilities not subject to fair value recognition by level within the valuation hierarchy:
		March 31, 2014						December 31, 2013
		Carrying Value		Fair Value		Fair Value		Carrying Value		Fair Value		Fair Value
				Level 2		Level 3				Level 2		Level 3
	(In thousands)
	Assets:
	Wellstat Diagnostics note receivable	$	50,191	$	—	$	52,194	$	47,694	$	—	$	46,042
	Hyperion	1,200		—		1,200		1,195		—		1,195
	AxoGen note receivable and embedded derivative	27,673		—		26,361		26,544		—		25,785
	Avinger note receivable	20,336		—		20,155		20,250		—		19,061
	LENSAR note receivable	39,581		—		40,000		39,572		—		39,572
	Durata note receivable	25,000		—		25,000		24,995		—		24,995
	Direct Flow Medical note receivable	34,926		—		35,859		34,799		—		34,799
	Paradigm Spine note receivable	49,493		—		49,493		—		—		—
	Total	$	248,400	$	—	$	250,262	$	195,049	$	—	$	191,449
	Liabilities:
	Series 2012 Notes	$	46,761	$	74,701	$	—	$	172,630	$	277,650	$	—
	May 2015 Notes	149,514		212,529		—		148,253		212,304		—
	February 2018 Notes	270,944		318,135		—		—		—		—
	Term loan	55,921		56,250		—		74,397		75,000		—
	Total	$	523,140	$	661,615	$	—	$	395,280	$	564,954	$	—
	As of March 31, 2014, the estimated fair value of our Paradigm Spine note receivable, as of March 31, 2014 and December 31, 2013, the estimated fair values of our Wellstat Diagnostics note receivable, Hyperion note receivable, AxoGen note receivable and derivative, Avinger note receivable, LENSAR note receivable, Durata note receivable and Direct Flow Medical note receivable, were determined using one or more discounted cash flow models, incorporating expected payments and the interest rate extended on the notes receivable with fixed interest rates and incorporating expected payments for notes receivable with a variable rate of return. In some instances the carrying values of certain notes receivable exceed their estimated fair market values. This is generally the result of discount rates used when performing a discounted cash flow for fair value valuation purposes. In all cases, the undiscounted expected future cash flows exceed the related carrying value.
	When deemed necessary we engage a third party valuation expert to evaluate our investments and the related inputs needed for us to estimate the fair value of certain investments. We determined our notes receivable assets are Level 3 assets as our valuations utilized significant unobservable inputs, including estimates of future revenues, discount rates, expectations about settlement, terminal values and required yield. To provide support for the estimated fair value measurements, we considered forward looking performance related to the investment and current measures associated with high yield indices, and reviewed the terms and yields of notes placed by specialty finance and venture firms both across industries and in similar sectors.
	The carrying value and estimated fair value of the AxoGen note include the value of a change of control embedded derivative valued at $1.1 million and $1.1 million at March 31, 2014, and December 31, 2013, respectively. We utilized discounted cash flows and probability analysis to estimate the fair value of the embedded derivative.
	The Wellstat Diagnostics note is collateralized by all assets and equity interest in Wellstat Diagnostics. The estimated fair value of the collateral was determined by using a discounted cash flow analysis related to the underlying technology included in the collateral. On March 31, 2014, the discounted cash flow was based upon expected income from estimated sales over a period of 15 years. The terminal value was estimated using selected market multiples based on sales and EBITDA. On December 31, 2013, the estimated fair value of Wellstat Diagnostics was determined by using a discounted cash flow that was based upon expected income from estimated sales through December 31, 2016.
	On March 31, 2014, the carrying value of the Avinger note approximates its fair value. We determined this note to be a Level 3 asset, as our valuation utilized significant unobservable inputs, including a discount rate of 19.5%, estimates of Avinger's future revenues, expectations about settlement and required yield. To provide support for the fair value measurement, we considered forward looking performance related to Avinger, current measures associated with high yield and Standard & Poor's Leveraged Commentary & Data indices, and reviewed the terms and yields of notes placed by specialty finance and venture firms both across industries and in a similar sector.
	The fair values of our convertible notes were determined using quoted market pricing or dealer quotes.

Cash_Equivalents_and_Investmen

Cash Equivalents and Investments	3 Months Ended
	Mar. 31, 2014
Cash and Cash Equivalents [Abstract]	'
Cash Equivalents and Investments	'
	4. Cash Equivalents and Investments
	As of March 31, 2014, and December 31, 2013, we had invested our excess cash balances primarily in money market funds, and a corporate security. Our securities are classified as available-for-sale and are carried at estimated fair value, with unrealized gains and losses reported in accumulated other comprehensive income (loss) in stockholders’ equity, net of estimated taxes. See Note 3 for fair value measurement information. The cost of securities sold is based on the specific identification method. To date, we have not experienced credit losses on investments in these instruments and we do not require collateral for our investment activities.
	Summary of Cash and Available-For-Sale Securities	Adjusted Cost		Unrealized Gains		Unrealized Losses		Estimated Fair Value		Cash and Cash Equivalents		Short-Term Investments
	(In thousands)
	31-Mar-14
	Cash	$	168,984	$	—	$	—	$	168,984	$	168,984	$	—
	Money market funds	165,051		—		—		165,051		165,051		—
	Corporate securities	3,500		58		—		3,558		—		3,558
	Total	$	337,535	$	58	$	—	$	337,593	$	334,035	$	3,558
	31-Dec-13
	Cash	$	8,332	$	—	$	—	$	8,332	$	8,332	$	—
	Money market funds	85,970		—		—		85,970		85,970		—
	Corporate securities	3,500		1,738		—		5,238		—		5,238
	Total	$	97,802	$	1,738	$	—	$	99,540	$	94,302	$	5,238
	No gains or losses on sales of available-for-sale securities were recognized for the three months ended March 31, 2014 and 2013.
	As of March 31, 2014, and December 31, 2013, all available-for-sale debt securities have contractual maturities of less than one year.

Foreign_Currency_Hedging

Foreign Currency Hedging	3 Months Ended
	Mar. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Foreign Currency Hedging	'
	5. Foreign Currency Hedging
	We designate the foreign currency exchange contracts used to hedge our royalty revenues based on underlying Euro-denominated sales as cash flow hedges. Euro forward contracts are presented on a net basis on our Condensed Consolidated Balance Sheets as we have entered into a netting arrangement with the counterparty. As of March 31, 2014, and December 31, 2013, all outstanding Euro forward contracts were classified as cash flow hedges.
	In January 2012, we modified our existing Euro forward and option contracts related to our licensees’ sales through December 2012 into Euro forward contracts with more favorable rates. Additionally, we entered into a series of Euro forward contracts covering the quarters in which our licensees’ sales occur through December 2014.
	The notional amounts, Euro exchange rates and fair values of our Euro forward contracts designated as cash flow hedges were as follows:
	Euro Forward Contracts					March 31, 2014							December 31, 2013
						(In thousands)							(In thousands)
	Currency	Settlement Price		Type		Notional Amount				Fair Value			Notional Amount		Fair Value
		($ per Euro)
	Euro	1.24		Sell Euro		$	10,850			$	(1,197	)	$	10,850	$	(1,207	)
	Euro	1.27		Sell Euro		44,450				(3,710		)	44,450		(3,760		)
	Euro	1.281		Sell Euro		36,814				(2,739		)	36,814		(2,785		)
	Euro	1.3		Sell Euro		—				—			19,500		(1,119		)
	Total					$	92,114			$	(7,646	)	$	111,614	$	(8,871	)
	The location and fair values of our Euro contracts in our Condensed Consolidated Balance Sheets were as follows:
	Cash Flow Hedge	Location		March 31,				December 31,
				2014				2013
	(In thousands)
	Euro contracts	Accrued liabilities		$	7,646			$	7,355
	Euro contracts	Other long-term liabilities		$	—			$	1,516
	The effect of our derivative instruments in our Condensed Consolidated Statements of Income and our Condensed Consolidated Statements of Comprehensive Income was as follows:
		Three Months Ended
		March 31,
		2014				2013
	(In thousands)
	Net gain (loss) recognized in OCI, net of tax (1)	$	67			$	3,568
	Gain (loss) reclassified from accumulated OCI into royalty revenue, net of tax (2)	$	(728	)		$	(1,247	)
	Net gain (loss) recognized in interest and other income, net -- cash flow hedges (3)	$	2			$	3
	_______________________________
	(1) Net change in the fair value of the effective portion of cash flow hedges classified in OCI.
	(2) Effective portion classified as royalty revenue.
	(3) Ineffectiveness from excess hedge was approximately ($2) and ($3) for the three months ended March 31, 2014 and 2013, respectively. Net loss from restructuring hedges was zero for the three months ended March 31, 2014 and 2013.

Notes_Receivable_and_Other_Lon

Notes Receivable and Other Long-term Receivables	3 Months Ended
	Mar. 31, 2014
Receivables [Abstract]	'
Notes and Other Long-term Receivables	'
	6. Notes Receivable and Other Long-term Receivables
	Notes receivable and other long-term receivables included the following significant agreements:
	Wellstat Diagnostics Note Receivable and Credit Agreement
	In March 2012, the Company executed a $7.5 million two-year senior secured note receivable with the holders of the equity interests in Wellstat Diagnostics. In addition to bearing interest at 10% per annum, the note gave PDL certain rights to negotiate for certain future financing transactions. In August 2012, PDL and the borrowers amended the note receivable, providing a senior secured note receivable of $10.0 million, bearing interest at 12% per annum, to replace the original $7.5 million note. This $10.0 million note was repaid on November 2, 2012, using the proceeds of the $40.0 million credit facility entered into with the Company on the same date.
	On November 2, 2012, the Company and Wellstat Diagnostics entered into a $40.0 million credit agreement pursuant to which the Company is to accrue quarterly interest payments at the rate of 5% per annum (payable in cash or in kind). In addition, PDL will receive quarterly royalty payments based on a low double digit royalty rate of Wellstat Diagnostics' net revenues, generated by the sale, distribution or other use of Wellstat Diagnostics' products, if any, commencing upon the commercialization of its products.
	In January 2013, the Company was informed that, as of December 31, 2012, Wellstat Diagnostics had used funds contrary to the terms of the credit agreement and breached Sections 2.1.2 and 7 of the credit agreement. PDL sent Wellstat Diagnostics a notice of default on January 22, 2013, and accelerated the amounts owed under the credit agreement. In connection with the notice of default, PDL exercised one of its available remedies and transferred approximately $8.1 million of available cash from a bank account of Wellstat Diagnostics to PDL and applied the funds to amounts due under the credit agreement. On February 28, 2013, the parties entered into a forbearance agreement whereby PDL agreed to refrain from exercising additional remedies for 120 days while Wellstat Diagnostics raised funds to capitalize the business and the parties attempted to negotiate a revised credit agreement. PDL agreed to provide up to $7.9 million to Wellstat Diagnostics to fund the business for the 120-day forbearance period under the terms of the forbearance agreement. Following the conclusion of the forbearance period that ended on June 28, 2013, the Company agreed to forbear its exercise of remedies for additional periods of time to allow the owners and affiliates of Wellstat Diagnostics to complete a pending financing transaction. During such forbearance period, the Company provided approximately $1.3 million to Wellstat Diagnostics to fund ongoing operations of the business. During the year ended December 31, 2013, approximately $8.7 million was advanced pursuant to the forbearance agreement, and no further advances have been provided by the Company to Wellstat Diagnostics during the three months ended March 31, 2014.
	On August 15, 2013, the owners and affiliates of Wellstat Diagnostics completed a financing transaction to fulfill its obligations under the forbearance agreement. On August 15, 2013, the Company entered into an amended and restated credit agreement with Wellstat Diagnostics. The Company determined that the new agreement should be accounted for as a modification of the existing agreement.
	Except as otherwise described here, the material terms of the amended and restated credit agreement are substantially the same as those of the original credit agreement, including quarterly interest payments at the rate of 5% per annum (payable in cash or in kind). In addition, PDL will continue to receive quarterly royalty payments based on a low double digit royalty rate of Wellstat Diagnostics' net revenues. However, pursuant to the amended and restated credit agreement: (i) the principal amount was reset to approximately $44.1 million which was comprised of approximately $33.7 million original loan principal and interest, $1.3 million term loan principal and interest and $9.1 million forbearance principal and interest; (ii) the specified internal rates of return increased; (iii) the default interest rate was increased; (iv) Wellstat Diagnostics' obligation to provide certain financial information increased in frequency to monthly; (v) internal financial controls were strengthened by requiring Wellstat Diagnostics to maintain an independent, third-party financial professional with control over fund disbursements; (vi) the Company waived the existing events of default; and (vii) the owners and affiliates of Wellstat Diagnostics are required to contribute additional capital to Wellstat Diagnostics upon the sale of an affiliate entity. The amended and restated credit agreement continues to have an ultimate maturity date of December 31, 2021 (but may mature earlier upon certain specified events).
	When the principal amount was reset, a $2.5 million reduction of the carrying value was recorded as a financing cost as a component of interest and other income, net. The new carrying value is lower as a function of the variable nature of the internal rate of return to be realized by the Company based on when the note is repaid. The internal rate of return calculation, although increased, was reset when the credit agreement was amended and restated.
	Wellstat Diagnostics may prepay the amended credit agreement at a price that, together with interest and royalty payments already made to the Company, would generate a specified internal rate of return to the Company. In the event of a change of control, bankruptcy or certain other customary events of defaults, or Wellstat Diagnostics' failure to achieve a specified annual revenue threshold in 2017, Wellstat Diagnostics will be required to prepay the credit agreement at a price that, together with interest and royalty payments already made to the Company, would generate a specified internal rate of return to the Company. The amended credit agreement is secured by a pledge of all of the assets of Wellstat Diagnostics, a pledge of all of Wellstat Diagnostics’ equity interests by the holders thereof, and a second lien on the assets of the affiliates of Wellstat Diagnostics.
	At March 31, 2014, and December 31, 2013, the carrying value of the note was included in non-current assets.
	As of March 31, 2014, the Company determined that its interest in Wellstat Diagnostics represented a variable interest in a Variable Interest Entity since Wellstat Diagnostics' equity was not sufficient to finance its operations without amounts advanced to it under the Company's note and forbearance agreement. However, the Company does not have the power to direct the activities of Wellstat Diagnostics that most significantly impacts Wellstat Diagnostic's economic performance and is not the primary beneficiary of Wellstat Diagnostics; therefore, Wellstat Diagnostics is not subject to consolidation.
	As of March 31, 2014, the carrying value of all amounts advanced to Wellstat Diagnostics including accrued interest was $50.2 million, which was recorded in notes receivable. As of March 31, 2014, the maximum loss exposure was $50.2 million.
	We believe that Wellstat Diagnostics does not currently have sufficient capital to execute its business plan.  Wellstat Diagnostics is considering other sources of financing and strategic alternatives, including selling the company. Depending on the outcome of its efforts and PDL's assessment of Wellstat Diagnostics's financial viability, we may recognize an impairment in a future period. The Company completed an impairment analysis for the quarter ended March 31, 2014. The estimated fair value of the collateral was determined to be approximately $52.2 million. The estimated fair value of the collateral was determined by using a discounted cash flow analysis related to the underlying technology included in the collateral. The discounted cash flow was based upon expected income from sales of planned products over a period of 15 years. The terminal value was estimated using selected market multiples based on sales and EBITDA.
	Hyperion Agreement
	On January 27, 2012, PDL and Hyperion entered into an agreement whereby Hyperion sold to PDL the royalty streams due from SDK related to a certain patent license agreement between Hyperion and SDK dated December 31, 2008. The agreement assigned the patent license agreement royalty stream accruing from January 1, 2012 through December 31, 2013 to PDL in exchange for the lump sum payment to Hyperion of $2.3 million. In exchange for the lump sum payment, PDL was to receive two equal payments of $1.2 million on both March 5, 2013 and March 5, 2014. The first payment of $1.2 million was paid on March 5, 2013. The second and final payment of $1.2 million was due on March 5, 2014. Hyperion did not make its scheduled payment on March 5, 2014. The Company completed an impairment analysis for the quarter ended March 31, 2013. The estimated fair value of the collateral was determined to be in excess of that of the carrying value. Hyperion is considering other sources of financing and strategic alternatives, including selling the company. Depending on the outcome of its efforts and PDL's assessment of Hyperion's financial viability, we may recognize an impairment in a future period.
	Merus Labs Note Receivable and Credit Agreement
	In July 2012, PDL loaned $35.0 million to Merus Labs in connection with its acquisition of a commercial-stage pharmaceutical product and related assets. In addition, PDL agreed to provide a $20.0 million letter of credit on behalf of Merus Labs for the seller of the assets to draw upon to satisfy the remaining $20.0 million purchase price obligation. The seller made this draw on the letter of credit in July 2013 and an additional loan to Merus Labs for $20.0 million was recorded for an aggregate of $55.0 million in total borrowings.
	Outstanding borrowings under the July 2012 loan bore interest at the rate of 13.5% per annum and outstanding borrowings as a result of the draw on the letter of credit bore interest at the rate of 14.0% per annum. Merus Labs was required to make four periodic principal payments in respect of the July 2012 loan, with repayment of the remaining principal balance of all loans due on March 31, 2015. The borrowings were subject to mandatory prepayments upon certain asset dispositions or debt issuances as set forth in the credit agreement. Merus Labs made the first of these payments in December 2012 in the amount of $5.0 million, and made the second payment in June 2013 in the amount of $7.5 million.
	In September 2013, Merus Labs prepaid in full its obligations under the credit agreement, including accrued interest through the payment date and a prepayment fee of 1% of the aggregate principal amount outstanding at the time of repayment. There was no outstanding balance owed as of March 31, 2014.
	AxoGen Note Receivable and Royalty Agreement
	In October 2012, PDL entered into the Royalty Agreement with AxoGen pursuant to which the Company will receive specified royalties on AxoGen’s net revenues (as defined in the Royalty Agreement) generated by the sale, distribution or other use of AxoGen’s products. The Royalty Agreement has an eight year term and provides PDL with royalties of 9.95% based on AxoGen's net revenues, subject to agreed-upon guaranteed quarterly minimum payments of approximately $1.3 to $2.3 million beginning in the fourth quarter of 2014, and the right to require AxoGen to repurchase the Royalty Agreement at the end of the fourth year. AxoGen has been granted certain rights to call the contract in years five through eight. The total consideration PDL paid to AxoGen for the royalty rights was $20.8 million, including an interim funding of $1.8 million in August 2012. AxoGen was required to use a portion of the proceeds from the Royalty Agreement to pay the outstanding balance under its existing credit facility. AxoGen plans to use the remainder of the proceeds to support the business plan for its products. The royalty rights are secured by the cash and accounts receivable of AxoGen.
	Under the Royalty Agreement, beginning on October 1, 2016, or in the event of the occurrence of a material adverse event, AxoGen's bankruptcy or material breach of the Royalty Agreement, the Company may require AxoGen to repurchase the royalty rights at a price that, together with payments already made by AxoGen, would generate a specified internal rate of return to the Company. The Company has concluded that the repurchase option is an embedded derivative which should be bifurcated and separately accounted for at fair value.
	In the event of a change of control, AxoGen must repurchase the assigned interests from the Company for a repurchase price equal to an amount that, together with payments already made by AxoGen, would generate a 32.5% internal rate of return to the Company. The Company has concluded that the change of control provision is an embedded derivative that should be bifurcated and separately recorded at its estimated fair value. The estimated fair value of the change of control provision was approximately $1.1 million and $1.1 million as of March 31, 2014, and December 31, 2013, respectively. The estimated fair value of this embedded derivative is included in the carrying value of the AxoGen note receivable. The Company recognized approximately $0.1 million and zero related to the change in the estimated fair value of embedded derivative during the three month periods ended March 31, 2014 and 2013, respectively.
	At any time after September 30, 2016, AxoGen, at its option, can repurchase the assigned interests under the Royalty Agreement for a price applicable in a change of control.
	During the term of the Royalty Agreement, the Company is entitled to designate an individual to be a member of AxoGen's board of directors. The Company has exercised this right and on October 5, 2012, upon the close of the transaction, the Company's President and Chief Executive Officer was elected to AxoGen's board of directors.
	On August 14, 2013, PDL purchased 1,166,666 shares of AXGN at $3.00 per share, totaling $3.5 million. The shares are classified as available for sale and recorded as short term investments on the balance sheet. As of March 31, 2014, the shares were valued at $3.6 million, which results in an unrealized gain of $0.1 million and is recorded in other comprehensive income.
	Avinger Note Receivable and Royalty Agreement
	On April 18, 2013, PDL entered into a credit agreement with Avinger, under which we made available to Avinger up to $40.0 million to be used by Avinger in connection with the commercialization of its lumivascular catheter devices and the development of Avinger's lumivascular atherectomy device. Of the $40.0 million available to Avinger, we funded an initial $20.0 million, net of fees, at the close of the transaction. Upon the attainment by Avinger of a certain revenue milestone to be accomplished no later than the end of the first half of 2014, the Company will fund Avinger an additional amount between $10.0 million and $20.0 million (net of fees) at Avinger's election. Outstanding borrowings under the initial loan bear interest at a stated rate of 12% per annum, and any future outstanding borrowings as a result of an additional amount funded upon reaching the revenue milestone will bear interest at the rate of 14% per annum.
	Avinger is required to make quarterly interest and principal payments. Principal repayment will commence on: (i) the eleventh interest payment date if the revenue milestone is not achieved or (ii) the thirteenth interest payment date if the revenue milestone is achieved. The principal amount outstanding at commencement of repayment, after taking into account any payment-in-kind, will be repaid in equal installments until final maturity of the loans. The loans will mature in April 2018.
	In connection with entering into the credit agreement, the Company will receive a low, single-digit royalty on Avinger's net revenues through April 2018. Avinger may prepay the outstanding principal and accrued interest on the notes receivable at any time. If Avinger repays the notes receivable prior to April 2018, the royalty on Avinger's net revenues will be reduced by 50% and will be subject to certain minimum payments from the prepayment date through April 2018.
	The obligations under the credit agreement are secured by a pledge of substantially all of the assets of Avinger and any of its subsidiaries (other than controlled foreign corporations, if any). The credit agreement provides for a number of standard events of default, including payment, bankruptcy, covenant, representation and warranty and judgment defaults.
	LENSAR Credit Agreement
	On October 1, 2013, PDL entered into a credit agreement with LENSAR, under which PDL made available to LENSAR up to $60 million to be used by LENSAR in connection with the commercialization of its currently marketed LENSAR Laser System. Of the $60 million available to LENSAR, an initial $40 million, net of fees, was funded by the Company at the close of the transaction. Upon attainment by LENSAR of a specified sales milestone to be accomplished no later than September 30, 2014, PDL will fund LENSAR an additional $20 million. Outstanding borrowings under the loans bear interest at the rate of 15.5% per annum, payable quarterly in arrears.
	Principal repayment will commence on the thirteenth interest payment date or December 31, 2016. The principal amount outstanding at the commencement of repayment will be repaid in equal installments until final maturity of the loans. The loans will mature on October 1, 2018. LENSAR may elect to prepay the loans at any time, subject to a prepayment penalty that decreases over the life of the loans. The loans are secured by all of the assets of LENSAR.
	Durata Credit Agreement
	On October 31, 2013, PDL entered into a credit agreement with Durata, under which the Company made available to Durata up to $70.0 million. Of the $70.0 million available to Durata, an initial $25.0 million (tranche one), net of fees, was funded by the Company at the close of the transaction. Upon marketing approval of dalbavancin in the United States, to be accomplished no later than December 31, 2014 (the tranche two milestone), the Company will fund Durata an additional $15 million (tranche two). Within 9 months after the occurrence of the tranche two milestone, Durata may request up to a single additional $30 million borrowing. Until the occurrence of the tranche two milestone, outstanding borrowings under tranche one bear interest at the rate of 14.0% per annum, payable quarterly in arrears. Upon occurrence of the tranche two milestone, the interest rate of the loans will decrease to 12.75%.
	Principal repayment will commence on the fifth interest payment date, March 31, 2015. The principal amount outstanding will be repaid quarterly over the remainder of the loans in an increasing percentage of the principal outstanding at commencement of repayment. The loans will mature on October 31, 2018. Durata may elect to prepay the loans at any time, subject to a prepayment penalty that decreases over the life of the loans. The Company is entitled to receive a fee in addition to the prepayment penalty in the event that Durata undergoes a change in control. The obligations under the credit agreement are secured by a pledge of substantially all of the assets of Durata.
	Direct Flow Credit Agreement
	On November 5, 2013, PDL entered into a credit agreement with Direct Flow Medical, under which PDL will provide up to $50.0 million to Direct Flow Medical. Of the $50.0 million available to Direct Flow Medical, an initial $35.0 million (tranche one), net of fees, was funded by the Company at the close of the transaction. Upon the attainment of a specified revenue milestone to be accomplished no later than December 31, 2014 (the tranche two milestone), the Company will fund Direct Flow Medical an additional $15.0 million, net of fees. Until the occurrence of the tranche two milestone, outstanding borrowings under tranche one bear interest at the rate of 15.5% per annum, payable quarterly in arrears. Upon occurrence of the tranche two milestone, the interest rate of the loans will decrease to 13.5%. Principal repayment will commence on the twelfth interest payment date, September 30, 2016. The principal amount outstanding at commencement of repayment will be repaid in equal installments until final maturity of the loans. The loans will mature on November 5, 2018. Direct Flow Medical may elect to prepay the loans at any time, subject to a prepayment penalty that decreases over the life of the loans. The obligations under the credit agreement are secured by a pledge of substantially all of the assets of Direct Flow Medical and any of its subsidiaries.
	Paradigm Spine Credit Agreement
	On February 14, 2014, the Company entered into a credit agreement with Paradigm Spine, under which it made available to Paradigm Spine up to $75.0 million to be used by Paradigm Spine to refinance its existing credit facility and expand its domestic commercial operations. Of the $75.0 million available to Paradigm Spine, an initial $50 million, net of fees, was funded by the Company at the close of the transaction. Upon the attainment of specified sales and other milestones before December 31, 2014, the Company will fund Paradigm Spine between an additional $6.25 million and $12.5 million, at Paradigm Spine’s discretion. Upon the attainment of specified sales and other milestones before June 30, 2015, the Company will fund Paradigm Spine up to an additional $12.5 million, also at Paradigm Spine’s discretion. Borrowings under the credit agreement bear interest at the rate of 13.0% per annum, payable quarterly in arrears.
	Principal repayment will commence on the twelfth interest payment date, December 31, 2016. The principal amount outstanding at commencement of repayment will be repaid in equal installments until final maturity of the loans. The loans will mature on February 14, 2019, or, if Paradigm Spine has achieved the first milestone and the additional loan amount is provided to Paradigm, the loans will mature on August 14, 2019. Paradigm Spine may elect to prepay the loans at any time, subject to a prepayment penalty that decreases over the life of the loans. The obligations under the credit agreement are secured by a pledge of substantially all of the assets of Paradigm Spine and its domestic subsidiaries and, initially, certain assets of Paradigm Spine’s German subsidiaries.
	For carrying value and fair value information related to our notes receivable and other long-term receivables, see Note 3.

Intangible_Assets_Notes

Intangible Assets (Notes)	3 Months Ended
	Mar. 31, 2014
Intangible Assets [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	7. Intangible Assets
	Depomed Royalty Purchase and Sales Agreement
	On October 18, 2013, PDL entered into a royalty purchase and sale agreement with Depomed and Depo DR Sub, LLC, a wholly owned subsidiary of Depomed, whereby the Company acquired the rights to receive royalties and milestones payable on sales of Type 2 diabetes products licensed by Depomed in exchange for a $240.5 million cash payment. Total arrangement consideration was $241.3 million, which was comprised of the $240.5 million cash payment to Depomed and $0.8 million in transaction costs.
	The rights acquired include Depomed’s royalty and milestone payments accruing from and after October 1, 2013: (a) from Santarus with respect to sales of Glumetza® (metformin HCL extended-release tablets) in the United States; (b) from Merck with respect to sales of Janumet® XR (sitagliptin and metformin HCL extended-release); (c) from Janssen Pharmaceutica with respect to potential future development milestones and sales of its investigational fixed-dose combination of Invokana® (canagliflozin) and extended-release metformin; (d) from Boehringer Ingelheim with respect to potential future development milestones and sales of the investigational fixed-dose combinations of drugs and extended-release metformin subject to Depomed’s license agreement with Boehringer Ingelheim; and (e) from LG Life Sciences and Valeant Pharmaceuticals for sales of extended-release metformin in Korea and Canada, respectively.
	Under the terms of the royalty agreement, the Company will receive all royalty and milestone payments due under license agreements between Depomed and its licensees until the Company has received payments equal to two times the cash payment it made to Depomed, after which all net payments received by Depomed will be shared evenly between the Company and Depomed.
	The royalty agreement terminates on the third anniversary following the date upon which the later of the following occurs: (a) October 25, 2021, or (b) at such time as no royalty payments remain payable under any license agreement and each of the license agreements has expired by its terms.
	This transaction has been accounted for as the acquisition of intangible assets. An income approach was used for the purpose of allocating the purchase price based on the relative fair value of each intangible asset and in the determination of the useful life of each intangible asset. The intangible assets have finite lives ranging from three to nine years and will be amortized to cost of royalty revenues over the related periods. During the fourth quarter of 2013, we began receiving royalty revenues related to Glumetza and commenced amortization of the initial carrying value of the related intangible asset of $164.5 million. During the first quarter of 2014, we began receiving royalty revenues related to Janumet XR and commenced amortization of the initial carrying value of the related intangible asset of $3.7 million. The intangible assets related to the other licensed products with a carrying value of $73.1 million and $76.8 million were not being amortized as of March 31, 2014, and December 31, 2013, as no revenues were recognized related to those intangible assets in 2013 and 2014. We will commence amortization of those intangible assets when the Company receives royalty revenues related to sales of the related products.
	The fair value of the intangible assets acquired was determined by using a discounted cash flow analysis related to the expected future cash flows to be generated by each licensed product. The discounted cash flow was based upon expected royalties from sales of licensed products over periods up to nine years. We determined that the intangible assets were Level 3 assets, as our valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future commercialization for products not yet approved by the FDA or other regulatory agencies.
	As of March 31, 2014, and December 31, 2013, the carrying value of the intangible assets acquired in our consolidated balance sheet was approximately $223.7 million and $235.7 million, respectively. As of March 31, 2014, the maximum loss exposure was $223.7 million.
	The following table summarizes the components of gross and net intangible assets balances as of March 31, 2014, and December 31, 2013:
		March 31, 2014							December 31, 2013
	(in thousands)	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
	Definite lived intangible assets	$	241,314	$	(17,568	)	$	223,746	$	241,314	$	(5,637	)	$	235,677
	As of March 31, 2014, the remaining weighted-average amortization period for acquired intangible asset is 7.8 years. The expected annual amortization expense related to the acquired intangible assets is as follows, (in thousands):
	2014 (remaining nine months)	$	25,202
	2015	44,235
	2016	32,661
	2017	18,726
	2018	17,798
	Thereafter	85,124
	Total	$	223,746
	As of March 31, 2014, and December 31, 2013, the Company determined that its royalty purchase interest in Depo DR Sub represented a variable interest in a variable interest entity since the equity in Depo DR Sub was not sufficient to finance its operations without additional financing. However, the Company does not have the power to direct the activities of Depo DR Sub that most significantly impact Depo DR Sub's economic performance and is not the primary beneficiary of Depo DR Sub; therefore, Depo DR Sub is not subject to consolidation by the Company.
	PDL is currently engaged in ongoing discussions with the SEC staff after receiving a comment letter to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013 that requested additional information about the Company’s accounting for the royalty purchase and sale agreement with Depomed. The Company currently classifies the asset as an intangible asset and is being asked to support its position and explain why it is not a financial asset. If the SEC or its staff do not agree with our conclusions, we may revise our accounting for the Depomed transaction, either prospectively or retrospectively. While we do not believe that any potential revision would result in a material impact on our financial statements we can give no assurance as such until we receive final clearance on our SEC comment letter, which is expected prior to our next 10-Q filing.

Accrued_Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2014
Payables and Accruals [Abstract]	'
Accrued Liabilities	'
	. Accrued Liabilities
		March 31,		December 31,
		2014		2013
	(In thousands)
	Compensation	$	1,314	$	768
	Interest	4,175		2,925
	Foreign currency hedge	7,646		7,355
	Dividend payable	72,243		59
	Legal	814		324
	Other	838		426
	Total	$	87,030	$	11,857

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	. Commitments and Contingencies
	Legal Proceedings
	Resolution of Past Challenges to the Queen et al. Patents in the United States and Europe
	Settlement with Novartis
	On February 25, 2011, we reached a settlement with Novartis. Under the settlement agreement, PDL agreed to dismiss its claims against Novartis in its action in Nevada state court which also includes Genentech and Roche as defendants. Novartis agreed to withdraw its opposition appeal in the EPO challenging the validity of the ‘216B Patent. Under the settlement agreement with Novartis, we will pay Novartis certain amounts based on net sales of Lucentis made by Novartis during calendar year 2011 and beyond. The settlement does not affect our claims against Genentech and Roche in the Nevada state court action. We do not currently expect such amount to materially impact our total annual revenues.
	Genentech / Roche Matter
	Settlement Agreement
	On January 31, 2014, we entered into a settlement agreement with Genentech and Roche which resolves all outstanding legal disputes between the parties, including our Nevada litigation with Genentech relating to an August 2010 facsimile sent by Genentech on behalf of Roche and Novartis asserting its products do not infringe on PDL’s SPC’s, and our arbitration proceedings with Genentech related to the audit of royalties on sales.
	Under the terms of the settlement agreement, effective retroactively to August 15, 2013, Genentech will pay a fixed royalty rate of 2.125 percent on worldwide sales of all its licensed products, as compared to the previous tiered royalty rate in the U.S and the fixed rate on all ex-U.S. based manufactured and sold licensed products. Pursuant to the agreement, Genentech and Roche confirmed that Avastin, Herceptin, Lucentis, Xolair and Perjeta are licensed products as defined in the relevant license agreements between the parties, and further agreed that Kadcyla and Gazyva are licensed products. Genentech will pay these royalties on all worldwide sales of Avastin, Herceptin, Xolair, Perjeta and Kadcyla occurring on or before December 31, 2015. With respect to Lucentis, Genentech owes no royalties on U.S. sales occurring after June 30, 2013, and will pay a royalty of 2.125 percent on all ex-U.S. sales occurring on or before December 28, 2014. The royalty term for Gazyva remains unchanged from the existing license agreement pertaining thereto.
	The agreement precludes Genentech and Roche from challenging the validity of PDL’s patents, including its SPCs in Europe, from contesting their obligation to pay royalties, from contesting patent coverage for Avastin, Herceptin, Lucentis, Xolair, Perjeta, Kadcyla and Gazyva and from assisting or encouraging any third party in challenging PDL’s patents and SPCs. The agreement further outlines the conduct of any audits initiated by PDL of the books and records of Genentech in an effort to ensure a full and fair audit procedure. Finally, the agreement clarifies that the sales amounts from which the royalties are calculated does not include certain taxes and discounts.
	Other Legal Proceedings
	In addition, from time to time, we are subject to various other legal proceedings and claims that arise in the ordinary course of business and that we do not expect to materially impact our financial statements.
	Lease Guarantee
	In connection with the Spin-Off, we entered into amendments to the leases for our former facilities in Redwood City, California, under which Facet was added as a co-tenant, and a Co-Tenancy Agreement, under which Facet agreed to indemnify us for all matters related to the leases attributable to the period after the Spin-Off date. Should Facet default under its lease obligations, we could be held liable by the landlord as a co-tenant and, thus, we have in substance guaranteed the payments under the lease agreements for the Redwood City facilities. As of March 31, 2014, the total lease payments for the duration of the guarantee, which runs through December 2021, are approximately $87.4 million. In April 2010, Abbot Laboratories acquired Facet and later renamed the entity AbbVie Biotherapeutics, Inc. If AbbVie were to default, we could also be responsible for lease related costs including utilities, property taxes and common area maintenance, which may be as much as the actual lease payments.
	We have recorded a liability of $10.7 million on our Condensed Consolidated Balance Sheets as of March 31, 2014, and December 31, 2013, related to this guarantee. In future periods, we may adjust this liability for any changes in the ultimate outcome of this matter that are both probable and estimable.

Convertible_Notes

Convertible Notes	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Convertible and Non-Recourse Notes	'
	. Convertible Notes and Term Loans
					Principal Balance Outstanding				Carrying Value
					March 31,				March 31,		December 31,
	Description		Maturity Date		2014				2014		2013
	(In thousands)
	Convertible Notes
	Series 2012 Notes		February 15, 2015		$	48,311			$	46,761	$	172,630
	May 2015 Notes		May 1, 2015		$	155,250			149,514		148,253
	February 2018 Notes		1-Feb-18		$	300,000			270,944		—
	Term loan		28-Oct-14		$	56,250			55,921		74,397
	Total								$	523,140	$	395,280
	As of March 31, 2014, PDL was in compliance with all applicable debt covenants, and embedded features of all debt agreements were evaluated and did not need to be accounted for separately.
	Series 2012 Notes
	In January 2012, we exchanged $169.0 million aggregate principal of new Series 2012 Notes for an identical principal amount of our February 2015 Notes, plus a cash payment of $5.00 for each $1,000 principal amount tendered, totaling approximately $845,000. The cash incentive payment was allocated to deferred issue costs of $765,000, additional paid-in capital of $52,000 and deferred tax assets of $28,000. The deferred issue costs will be recognized over the life of the Series 2012 Notes as interest expense. In February 2012, we entered into separate privately negotiated exchange agreements under which we exchanged an additional $10.0 million aggregate principal amount of the new Series 2012 Notes for an identical principal amount of our February 2015 Notes. In August 2013, the Company entered into a separate privately negotiated exchange agreement under which it retired the final $1.0 million aggregate principal amount of the Company's outstanding February 2015 Notes. Pursuant to the exchange agreement, the holder of the February 2015 Notes received $1.0 million aggregate principal amount of the Company's Series 2012 Notes. Immediately following the exchange, no principal amount of the February 2015 Notes remained outstanding and $180.0 million principal amount of the Series 2012 Notes was outstanding. On February 6, 2014, the Company entered into exchange and purchase agreements with certain holders of approximately $131.7 million aggregate principal amount of outstanding Series 2012 Notes. The exchange agreement provided for the issuance by the Company of shares of common stock and a cash payment for the Series 2012 Notes being exchanged, and the purchase agreement provided for a cash payment for the Series 2012 Notes being repurchased. The total consideration given was approximately $191.8 million. The Company issued to the participating holders of the February 2012 Notes, a total of approximately 20.3 million shares of its common stock with a fair value of approximately $157.6 million and made an aggregate cash payment of approximately $34.2 million pursuant to the exchange and purchase agreements. Of the $34.2 million cash payment, $2.5 million is attributable to a inducement fee, $1.8 million is attributable to interest accrued through the date of settlement and $29.9 million is attributable to the repurchase of the Series 2012 Notes. It was determined that the exchange and purchase agreement represented an extinguishment of the related notes. As a result, a loss on extinguishment of $6.1 million was recorded. The $6.1 million loss on extinguishment included the derecognition of original issuance discount of $5.8 million and a $0.3 million charge resulting from the difference of the face value of the notes and the fair value of the notes. Immediately following the exchange, $48.3 million principal amount of the Series 2012 Notes was outstanding with approximately $2.1 million of remaining original issuance discount to be amortized over the remaining life of the Series 2012 Notes.
	The terms of the Series 2012 Notes are governed by the indenture dated as of January 5, 2012, and include a net share settlement feature, meaning that if a conversion occurs, the principal amount will be settled in cash and the excess, if any, will be settled in the Company’s common stock. The Series 2012 Notes may not be redeemed by the Company prior to their stated maturity date. Our Series 2012 Notes are due February 15, 2015, and bear interest at a rate of 2.875% per annum, payable semi-annually in arrears on February 15 and August 15 of each year.
	Holders may convert their Series 2012 Notes at any time prior to the close of business on the second scheduled trading day immediately preceding the stated maturity date of the Series 2012 Notes under the following circumstances:
	•	During any fiscal quarter commencing after the fiscal quarter ending December 31, 2011, if the closing price of the Company’s common stock for at least 20 trading days in a period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter exceeds 130% of the conversion price for the Series 2012 Notes on the last day of such preceding fiscal quarter;
	•	During the five business-day period immediately after any five consecutive trading-day period in which the trading price per $1,000 principal amount of the Series 2012 Notes for each trading day of that measurement period was less than 98% of the product of the closing price of the Company’s common stock and the conversion rate for the Series 2012 Notes for that trading day;
	•	Upon the occurrence of certain corporate transactions as provided in the indenture; or
	•	Anytime, at the holder’s option, beginning on August 15, 2014.
	Holders of our Series 2012 Notes who convert their Series 2012 Notes in connection with a fundamental change resulting in the
	reclassification, conversion, exchange or cancellation of our common stock may be entitled to a make-whole premium in the form of an increase in the conversion rate. Such fundamental change is generally defined to include a merger involving PDL, an acquisition of a majority of PDL’s outstanding common stock and a change of a majority of PDL’s board of directors without the approval of the board of directors.
	We allocated $2.3 million of the remaining deferred February 2015 Notes original issue discount as of the date of the exchange to the Series 2012 Notes based on the percentage of the February 2015 Notes exchanged. In accordance with the accounting guidance for convertible debt instruments that may be settled in cash or other assets on conversion, we were required to separately account for the liability component of the instrument in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. As a result, we separated the principal balance of the Series 2012 Notes, net of the allocated original issue discount, between the fair value of the debt component and the common stock conversion feature. Using an assumed borrowing rate of 7.3%, which represents the estimated market interest rate for a similar nonconvertible instrument available to us during the period of the exchange transactions, we recorded a total debt discount of $16.8 million, allocated $10.9 million to additional paid-in capital and $5.9 million to deferred tax liability. The discount is being amortized to interest expense over the term of the Series 2012 Notes and increases interest expense during the term of the Series 2012 Notes from the 2.875% cash coupon interest rate to an effective interest rate of 7.3%. The common stock conversion feature is recorded as a component of stockholders’ deficit.
	The principal amount, carrying value and unamortized discount of our Series 2012 Notes were as follows:
	(In thousands)		March 31, 2014				December 31, 2013
	Principal amount of the Series 2012 Notes		$	48,311			$	180,000
	Unamortized discount of liability component		(1,550		)		(7,370		)
	Total		$	46,761			$	172,630
	Interest expense for our Series 2012 Notes on the Condensed Consolidated Statements of Income was as follows:
			Three Months Ended
			March 31,
	(In thousands)		2014				2013
	Contractual coupon interest		$	761			$	1,287
	Amortization of debt issuance costs		870				284
	Amortization of debt discount		980				1,487
	Total		$	2,611			$	3,058
	As of March 31, 2014, our Series 2012 Notes are convertible into 185.777 shares of the Company’s common stock per $1,000 of principal amount, or approximately $5.38 per common share, subject to further adjustment upon certain events including dividend payments. As of March 31, 2014, the remaining discount amortization period was 0.9 years.
	Our common stock exceeded the conversion threshold price of $7.12 per common share for at least 20 days during the 30 consecutive trading days ended December 31, 2013; accordingly, the Series 2012 Notes were convertible at the option of the holder during the quarter ended March 31, 2014. Our common stock price exceeded the conversion threshold price of $7.00 per common share for at least 20 days during the 30 consecutive trading days ended March 31, 2014; accordingly, the Series 2012 Notes are convertible at the option of the holder during the quarter ending June 30, 2014. The Series 2012 Notes have been classified as current as the notes will be due upon demand within one year of the quarter ended March 31, 2014. At March 31, 2014, the if-converted value of our Series 2012 Notes exceeded their principal amount by approximately $26.3 million.
	May 2015 Notes
	On May 16, 2011, we issued $155.3 million in aggregate principal amount, at par, of our May 2015 Notes in an underwritten public offering, for net proceeds of $149.7 million. Our May 2015 Notes are due May 1, 2015, and we pay interest at 3.75% on our May 2015 Notes semiannually in arrears on May 1 and November 1 of each year, beginning November 1, 2011. Proceeds from our May 2015 Notes, net of amounts used for purchased call option transactions and provided by the warrant transactions described below, were used to redeem our 2012 Notes. Upon the occurrence of a fundamental change, as defined in the indenture, holders have the option to require PDL to repurchase their May 2015 Notes at a purchase price equal to 100% of the principal, plus accrued interest.
	Our May 2015 Notes are convertible under any of the following circumstances:
	•	During any fiscal quarter ending after the quarter ending June 30, 2011, if the last reported sale price of our common stock for at least 20 trading days in a period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter exceeds 130% of the conversion price for the notes on the last day of such preceding fiscal quarter;
	•	During the five business-day period immediately after any five consecutive trading-day period, which we refer to as the measurement period, in which the trading price per $1,000 principal amount of notes for each trading day of that measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate for the notes for each such day;
	•	Upon the occurrence of specified corporate events as described further in the indenture; or
	•	At any time on or after November 1, 2014.
	In accordance with the accounting guidance for convertible debt instruments that may be settled in cash or other assets on conversion, we were required to separately account for the liability component of the instrument in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. As a result, we separated the principal balance of our May 2015 Notes between the fair value of the debt component and the fair value of the common stock conversion feature. Using an assumed borrowing rate of 7.5%, which represents the estimated market interest rate for a similar nonconvertible instrument available to us on the date of issuance, we recorded a total debt discount of $18.9 million, allocated $12.3 million to additional paid-in capital and allocated $6.6 million to deferred tax liability. The discount is being amortized to interest expense over the term of our May 2015 Notes and increases interest expense during the term of our May 2015 Notes from the 3.75% cash coupon interest rate to an effective interest rate of 7.5%. As of March 31, 2014, the remaining discount amortization period is 1.1 years.
	The carrying value and unamortized discount of our May 2015 Notes were as follows:
	(In thousands)		March 31, 2014				December 31, 2013
	Principal amount of the May 2015 Notes		$	155,250			$	155,250
	Unamortized discount of liability component		(5,736		)		(6,997		)
	Total		$	149,514			$	148,253
	Interest expense for our May 2015 Notes on the Condensed Consolidated Statements of Income was as follows:
			Three Months Ended
			March 31,
	(In thousands)		2014				2013
	Contractual coupon interest		$	1,455			$	1,455
	Amortization of debt issuance costs		315				304
	Amortization of debt discount		1,261				1,173
	Total		$	3,031			$	2,932
	As of March 31, 2014, our May 2015 Notes are convertible into 162.7280 shares of the Company’s common stock per $1,000 of principal amount, or approximately $6.15 per common share, subject to further adjustment upon certain events including dividend payments.
	Our common stock exceeded the conversion threshold price of $8.13 for at least 20 days during the 30 consecutive trading days ended December 31, 2013; accordingly, the May 2015 Notes were not convertible at the option of the holder during the quarter ended March 31, 2014. Our common stock price did not exceed the conversion threshold price of $7.99 per common share for at least 20 days during the 30 consecutive trading days ended March 31, 2014; accordingly, the May 2015 Notes are not convertible at the option of the holder during the quarter ending June 30, 2014. At March 31, 2014, the if-converted value of our May 2015 exceeded their principal amount by approximately $54.7 million.
	Purchased Call Options and Warrants
	In connection with the issuance of our May 2015 Notes, we entered into purchased call option transactions with two hedge counterparties. We paid an aggregate amount of $20.8 million, plus legal fees, for the purchased call options with terms substantially similar to the embedded conversion options in our May 2015 Notes. The purchased call options cover, subject to anti-dilution and certain other customary adjustments substantially similar to those in our May 2015 Notes, approximately 25.3 million shares of our common stock. We may exercise the purchased call options upon conversion of our May 2015 Notes and require the hedge counterparty to deliver shares to the Company in an amount equal to the shares required to be delivered by the Company to the note holder for the excess conversion value. The purchased call options expire on May 1, 2015, or the last day any of our May 2015 Notes remain outstanding.
In addition, we sold to the hedge counterparties warrants exercisable, on a cashless basis, for the sale of rights to receive up to 27.5 million shares of common stock underlying our May 2015 Notes. We received an aggregate amount of $10.9 million for the sale from the two counterparties. The warrant counterparties may exercise the warrants on their specified expiration dates that occur over a period of time ending on January 20, 2016. If the VWAP of our common stock, as defined in the warrants, exceeds the strike price of the warrants on the date of conversion, we will deliver to the warrant counterparties shares equal to the spread between the VWAP on the date of exercise or expiration and the strike price. If the VWAP is less than the strike price, neither party is obligated to deliver anything to the other.
The purchased call option transactions and warrant sales effectively serve to reduce the potential dilution associated with conversion of our May 2015 Notes. The strike prices are approximately $6.15 and $7.23, subject to further adjustment upon certain events including dividend payments, for the purchased call options and warrants, respectively.
If the share price is above $6.15, but below $7.23, upon conversion of our May 2015 Notes, the purchased call options will offset the share dilution, because the Company will receive shares on exercise of the purchased call options equal to the shares that the Company must deliver to the note holders. If the share price is above $7.23, upon exercise of the warrants, the Company will deliver shares to the counterparties in an amount equal to the excess of the share price over $7.23. For example, a 10% increase in the share price above $7.23 would result in the issuance of 2.0 million incremental shares upon exercise of the warrants. If our share price continues to increase, additional dilution would occur.
While the purchased call options are expected to reduce the potential equity dilution upon conversion of our May 2015 Notes, prior to conversion or exercise, our May 2015 Notes and the warrants could have a dilutive effect on the Company’s earnings per share to the extent that the price of the Company’s common stock during a given measurement period exceeds the respective exercise prices of those instruments. As of March 31, 2014, and December 31, 2013, the market price condition for convertibility of our May 2015 Notes was not met and there were no related purchased call options or warrants exercised.
The purchased call options and warrants are considered indexed to PDL stock, require net-share settlement, and met all criteria for equity classification at inception and at March 31, 2014, and December 31, 2013. The purchased call options cost, including legal fees, of $20.8 million, less deferred taxes of $7.2 million, and the $10.9 million received for the warrants, was recorded as adjustments to additional paid-in capital. Subsequent changes in fair value will not be recognized as long as the purchased call options and warrants continue to meet the criteria for equity classification.
February 2018 Notes
On February 12, 2014, we issued $300 million in aggregate principal amount, at par, of our February 2018 Notes in an underwritten public offering, for net proceeds of $290.2 million. Our February 2018 Notes are due February 1, 2018, and we pay interest at 4.0% on our February 2018 Notes semiannually in arrears on February 1 and August 1 of each year, beginning August 1, 2014. A portion of the proceeds from our February 2018 Notes, net of amounts used for purchased call option transactions and provided by the warrant transactions described below, were used to redeem $131.7 million of our Series 2012 Notes. Upon the occurrence of a fundamental change, as defined in the indenture, holders have the option to require PDL to repurchase their February 2018 Notes at a purchase price equal to 100% of the principal, plus accrued interest.
Our February 2018 Notes are convertible under any of the following circumstances:
•	During any fiscal quarter ending after the quarter ending June 30, 2014, if the last reported sale price of our common stock for at least 20 trading days in a period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter exceeds 130% of the conversion price for the notes on the last day of such preceding fiscal quarter;
•	During the five business-day period immediately after any five consecutive trading-day period, which we refer to as the measurement period, in which the trading price per $1,000 principal amount of notes for each trading day of that measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate for the notes for each such day;
•	Upon the occurrence of specified corporate events as described further in the indenture; or
•	At any time on or after August 1, 2017.
The initial conversion rate for the February 2018 Notes is 109.1048 shares of Company common stock per $1,000 principal amount of February 2018 Notes, which is equivalent to an initial conversion price of approximately $9.17 per share of common stock, subject to adjustments upon the occurrence of certain specified events as set forth in the Indenture. Upon conversion, the Company will be required to pay cash and, if applicable, deliver shares of Company common stock as described in the Indenture.
In accordance with the accounting guidance for convertible debt instruments that may be settled in cash or other assets on conversion, we were required to separately account for the liability component of the instrument in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. As a result, we separated the principal balance of our February 2018 Notes between the fair value of the debt component and the fair value of the common stock conversion feature. Using an assumed borrowing rate of 7.0% which represents the estimated market interest rate for a similar nonconvertible instrument available to us on the date of issuance, we recorded a total debt discount of $29.7 million, allocated $19.3 million to additional paid-in capital and allocated $10.4 million to deferred tax liability. The discount is being amortized to interest expense over the term of our February 2018 Notes and increases interest expense during the term of our February 2018 Notes from the 4.0% cash coupon interest rate to an effective interest rate of 6.9%. As of March 31, 2014, the remaining discount amortization period is 3.8 years.
The carrying value and unamortized discount of our February 2018 Notes were as follows:
(In thousands)		March 31, 2014
Principal amount of the February 2018 Notes		$	300,000
Unamortized discount of liability component		(29,056		)
Total		$	270,944
Interest expense for our February 2018 Notes on the Condensed Consolidated Statements of Income was as follows:
		Three Months Ended
		March 31,
(In thousands)		2014
Contractual coupon interest		$	1,571
Amortization of debt issuance costs		222
Amortization of debt discount		671
Total		$	2,464
As of March 31, 2014, our February 2018 Notes are not convertible. At March 31, 2014, the if-converted value of our February 2018 Notes was less than the principal amount by approximately $28.0 million.
Purchased Call Options and Warrants
In connection with the issuance of our February 2018 Notes, we entered into purchased call option transactions with two hedge counterparties. We paid an aggregate amount of $31.0 million for the purchased call options with terms substantially similar to the embedded conversion options in our February 2018 Notes. The purchased call options cover, subject to anti-dilution and certain other customary adjustments substantially similar to those in our February 2018 Notes, approximately 32.7 million shares of our common stock. We may exercise the purchased call options upon conversion of our February 2018 Notes and require the hedge counterparty to deliver shares to the Company in an amount equal to the shares required to be delivered by the Company to the note holder for the excess conversion value. The purchased call options expire on February 1, 2018, or the last day any of our February 2018 Notes remain outstanding.
In addition, we sold to the hedge counterparties warrants exercisable, on a cashless basis, for the sale of rights to receive shares of common stock that will initially underlie our February 2018 Notes at a strike price of $10.3610 per share, which represents a premium of approximately 30% over the last reported sale price of the Company's common stock of $7.97 on February 6, 2014. The warrant transactions could have a dilutive effect to the extent that the market price of the Company's common stock exceeds the applicable strike price of the warrants on the date of conversion. We received an aggregate amount of $11.4 million for the sale from the two counterparties. The warrant counterparties may exercise the warrants on their specified expiration dates that occur over a period of time. If the VWAP of our common stock, as defined in the warrants, exceeds the strike price of the warrants, we will deliver to the warrant counterparties shares equal to the spread between the VWAP on the date of exercise or expiration and the strike price. If the VWAP is less than the strike price, neither party is obligated to deliver anything to the other.
The purchased call option transactions and warrant sales effectively serve to reduce the potential dilution associated with conversion of our February 2018 Notes. The strike prices are subject to further adjustment in the event that future quarterly dividends exceed $0.15 per share.
The purchased call options and warrants are considered indexed to PDL stock, require net-share settlement, and met all criteria for equity classification at inception and at March 31, 2014. The purchased call options cost of $31.0 million, less deferred taxes of $10.8 million, and the $11.4 million received for the warrants, was recorded as adjustments to additional paid-in capital. Subsequent changes in fair value will not be recognized as long as the purchased call options and warrants continue to meet the criteria for equity classification.
Term Loan
On October 28, 2013, PDL entered into a credit agreement among the Company, the lenders party thereto and the Royal Bank of Canada, as administrative agent. The initial Term Loan amount was for $75 million, with a term of one year.
The interest rates per annum applicable to amounts outstanding under the Term Loan are, at the Company’s option, either (a) the base rate plus 1.00%, or (b) the Eurodollar rate plus 2.00% per annum. As of March 31, 2014, the interest rate was 2.24%. Interest and the remaining principal payments associated with the Term Loan are due on the interest payment dates of April 30 and July 31 of 2014, with the remaining outstanding balance due on October 28, 2014.
Any future material domestic subsidiaries of the Company are required to guarantee the obligations of the Company under the Term Loan, except as otherwise provided. The Company’s obligations under the Term Loan are secured by a lien on a substantial portion of the Company's assets.
The Term Loan contains affirmative and negative covenants that the Company believes are usual and customary for a senior secured credit agreement. The Term loan also requires compliance with certain financial covenants, including a maximum total leverage ratio and a debt service coverage ratio, in each case calculated as set forth in the Term Loan and compliance with which may be necessary to take certain corporate actions. The Term Loan contains events of default that the Company believes are usual and customary for a senior secured credit agreement.

Other_LongTerm_Liabilities

Other Long-Term Liabilities	3 Months Ended
	Mar. 31, 2014
Other Liabilities Disclosure [Abstract]	'
Other Long-Term Liabilities	'
	11. Other Long-Term Liabilities
		March 31,		December 31,
		2014		2013
	(In thousands)
	Accrued lease liability	$	10,700	$	10,700
	Uncertain tax positions	13,346		10,826
	Long-term deferred tax liabilities	10,404		—
	Foreign currency hedge	—		1,516
	Total	$	34,450	$	23,042

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-Based Compensation	'
	12. Stock-Based Compensation
	The Company grants stock options and restricted stock awards pursuant to a stockholder approved stock-based incentive plan. This incentive plan is described in further detail in Note 15, Stock-Based Compensation, of Notes to Consolidated Financial Statements in the 2013 Form 10-K.
	The following table summarizes the Company’s stock option and restricted stock award activity during the three months ended March 31, 2014:
				Stock Options			Restricted Stock Awards
	(In thousands except per share amounts)	Shares Available for Grant		Number of Shares Outstanding	Weighted Average Exercise Price		Number of Shares Outstanding	Weighted Average Grant-date Fair Value Per Share
	Balance December 31, 2013	4,478		172	$	16.52	114	$	7.45
	Granted	(36	)	—			36	$	8.4
	Balance at March 31, 2014	4,442		172	$	16.52	150	$	7.68

Cash_Dividends

Cash Dividends	3 Months Ended
	Mar. 31, 2014
Stockholders' Equity Note [Abstract]	'
Cash Dividends	'
	13. Cash Dividends
	On January 29, 2014, our board of directors declared that the regular quarterly dividends to be paid to our stockholders in 2014 will be $0.15 per share of common stock, payable on March 12, June 12, September 12 and December 12 of 2014 to stockholders of record on March 5, June 5, September 5 and December 5 of 2014, the record dates for each of the dividend payments, respectively.
	In connection with the March 12, 2014, dividend payment, the conversion rates for our convertible notes adjusted as follows:
	Convertible Notes	Conversion Rate per $1,000 Principal Amount	Approximate Conversion Price Per Common Share		Effective Date
	Series 2012 Notes	185.777	$	5.38	March 3, 2014
	May 2015 Notes	162.728	$	6.15	March 3, 2014

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	14. Income Taxes
	For the three months ended March 31, 2014, and 2013, income tax expense was primarily derived by applying the federal statutory rate of 35% to operating income before income taxes.
	The uncertain tax position increased during the quarter ended March 31, 2014 by $2.4 million from the estimated state tax liability as a result of increased revenues. We expect to release tax liabilities related to uncertain tax positions related to federal tax credits taken on the 2009 income tax return in the third quarter of 2014 of approximately $6.5 million, and during the fourth quarter of 2014 of approximately $3.9 million, which will result in a reduction to income tax expense.
	In general, our income tax returns are subject to examination by tax authorities for tax years 1996 forward. The California Franchise Tax Board is currently examining the Company’s 2008, 2009 and 2010 tax returns. Although the timing of the resolution of income tax examinations is highly uncertain, and the amounts ultimately paid, if any, upon resolution of the issues raised by the taxing authorities may differ materially from the amounts accrued for each year, we do not anticipate any material change to the amount of our unrecognized tax benefits over the next 12 months, except as described above.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income (Loss)	3 Months Ended
	Mar. 31, 2014
Accumulated Other Comprehensive Income (Loss) [Abstract]	'
Accumulated Other Comprehensive Income (Loss)	'
	15. Accumulated Other Comprehensive Income (Loss)
	Comprehensive income is comprised of net income and other comprehensive income (loss). We include unrealized net gains on investments held in our available-for-sale securities and unrealized gains (losses) on our cash flow hedges in other comprehensive income (loss), and present the amounts net of tax. Our other comprehensive income (loss) is included in our Condensed Consolidated Statements of Comprehensive Income.
	The balance of accumulated other comprehensive income (loss), net of tax, was as follows:
		Unrealized gains (losses) on available-for-sale securities			Unrealized gains (losses) on cash flow hedges			Total Accumulated Other Comprehensive Income (Loss)
	(In thousands)
	Beginning Balance at December 31, 2013	$	1,129		$	(6,017	)	$	(4,888	)
	Activity for the three months ended March 31, 2014	(1,092		)	795			(297		)
	Ending Balance at March 31, 2014	$	37		$	(5,222	)	$	(5,185	)

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	16. Subsequent Event
	On April 1, 2014, PDL entered into a note purchase agreement with Accel 300, a wholly-owned subsidiary of kaléo. (formerly known as Intelliject, Inc.), pursuant to which the Company acquired $150 million of secured notes due 2029. The secured notes were issued pursuant to an indenture between Accel 300 and U.S. Bank, National Association, as trustee, and are secured by 100 percent of the royalties from kaléo’s first approved product, Auvi-Q™ (epinephrine auto-injection, USP) (known as Allerject in Canada), 10 percent of net sales of kaléo’s second proprietary auto-injector based product, EVZIO (naloxone hydrochloride injection) (collectively, the "Revenue Interests"), and by a pledge of kaléo’s equity ownership in Accel 300, LLC.
	The secured notes bear interest at 13 percent per annum, paid quarterly in arrears on principal outstanding. The principal balance of the secured notes is repaid to the extent that the Revenue Interests exceed the quarterly interest payment, as limited by a quarterly payment cap. The final maturity of the secured notes is March 2029. Kaléo may redeem the secured notes at any time, subject to a redemption premium.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Basis of Presentation, Policy	'
	Basis of Presentation
	The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with GAAP for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that management of PDL believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.
	The accompanying Condensed Consolidated Financial Statements and related financial information should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December 31, 2013, included in our Annual Report on Form 10-K filed with the SEC. The Condensed Consolidated Balance Sheet at December 31, 2013, has been derived from the audited Consolidated Financial Statements at that date.
Principles of Consolidation, Policy	'
	Principles of Consolidation
	The Condensed Consolidated Financial Statements include the accounts of PDL and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation. Our condensed consolidated financial statements are prepared in accordance with GAAP and the rules and regulations of the SEC.
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
Notes Receivable and Other Long-Term Receivables, Policy	'
	Notes Receivable and Other Long-Term Receivables
	We account for our notes receivable at amortized cost, net of unamortized origination fees, if any. Related fees and costs are recorded net of any amounts reimbursed. Interest is accreted or accrued to interest income using the interest method.
Customer Concentration, Policy	'
	Customer Concentration
	The percentage of total revenue recognized, which individually accounted for ten percent or more of our total revenues, was as follows:
			Three Months Ended March 31,
	Licensee	Product Name	2014		2013
	Genentech	Avastin®	29	%	36	%
		Herceptin®	27	%	33	%
		Lucentis®	12	%	13	%
	Biogen Idec1	Tysabri®	9	%	14	%
	Depomed	Glumetza®	17	%	0	%
Foreign Currency Hedging, Policy	'
	Foreign Currency Hedging
	We enter into foreign currency hedges to manage exposures arising in the normal course of business and not for speculative purposes.
	We hedge certain Euro-denominated currency exposures related to royalties associated with our licensees’ product sales with Euro forward contracts. In general, these contracts are intended to offset the underlying Euro market risk in our royalty revenues. These contracts currently extend through the fourth quarter of 2014. We designate foreign currency exchange contracts used to hedge royalty revenues based on underlying Euro-denominated licensee product sales as cash flow hedges.
	At the inception of each hedging relationship and on a quarterly basis, we assess hedge effectiveness. The fair value of the Euro contracts is estimated using pricing models with readily observable inputs from actively quoted markets and is disclosed on a gross basis. The aggregate unrealized gain or loss, net of tax, on the effective component of the hedge is recorded in stockholders’ equity as accumulated other comprehensive income (loss). Gains or losses on cash flow hedges are recognized as an adjustment to royalty revenue in the same period that the hedged transaction impacts earnings as royalty revenue. Any gain or loss on the ineffective portion of our hedge contracts is reported in interests and other income, net in the period the ineffectiveness occurs.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Schedule of Revenue by Major Customers	'
			Three Months Ended March 31,
	Licensee	Product Name	2014		2013
	Genentech	Avastin®	29	%	36	%
		Herceptin®	27	%	33	%
		Lucentis®	12	%	13	%
	Biogen Idec1	Tysabri®	9	%	14	%
	Depomed	Glumetza®	17	%	0	%

Net_Income_per_Share_Tables

Net Income per Share (Tables)	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Schedule of calculation of numerator and denominator in earnings per share	'
		Three Months Ended
		March 31,
	Net Income per Basic and Diluted Share:	2014		2013
	(in thousands except per share amounts)
	Numerator
	Net income used to compute net income per basic share	$	72,883	$	53,471
	Add back interest expense for convertible notes, net of estimated tax of approximately $0 and $3 for the three months ended March 31, 2014 and 2013, respectively	—		6
	Net income used to compute net income per diluted share	$	72,883	$	53,477
	Denominator
	Weighted-average shares used to compute net income per basic share	151,198		139,816
	Restricted stock outstanding	68		61
	Effect of dilutive stock options	21		18
	Assumed conversion of Series 2012 Notes	6,903		6,688
	Assumed conversion of May 2015 Notes	6,381		2,345
	Assumed conversion of February 2015 Notes	—		173
	Weighted-average shares used to compute net income per diluted share	164,571		149,101
	Net income per basic share	$	0.48	$	0.38
	Net income per diluted share	$	0.44	$	0.36

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Schedule of fair value of financial instruments measured on recurring basis	'
		March 31, 2014						December 31, 2013
		Level 1		Level 2		Total		Level 1		Level 2		Total
	(In thousands)
	Financial assets:
	Money market funds	$	165,051	$	—	$	165,051	$	85,970	$	—	$	85,970
	Corporate securities	—		3,558		3,558		—		5,238		5,238
	Total	$	165,051	$	3,558	$	168,609	$	85,970	$	5,238	$	91,208
	Financial liabilities:
	Foreign currency hedge contracts	$	—	$	7,646	$	7,646	$	—	$	8,871	$	8,871
Schedule of fair value of assets and liabilities not subject to fair value recognition by level within the valuation hierarchy	'
		March 31, 2014						December 31, 2013
		Carrying Value		Fair Value		Fair Value		Carrying Value		Fair Value		Fair Value
				Level 2		Level 3				Level 2		Level 3
	(In thousands)
	Assets:
	Wellstat Diagnostics note receivable	$	50,191	$	—	$	52,194	$	47,694	$	—	$	46,042
	Hyperion	1,200		—		1,200		1,195		—		1,195
	AxoGen note receivable and embedded derivative	27,673		—		26,361		26,544		—		25,785
	Avinger note receivable	20,336		—		20,155		20,250		—		19,061
	LENSAR note receivable	39,581		—		40,000		39,572		—		39,572
	Durata note receivable	25,000		—		25,000		24,995		—		24,995
	Direct Flow Medical note receivable	34,926		—		35,859		34,799		—		34,799
	Paradigm Spine note receivable	49,493		—		49,493		—		—		—
	Total	$	248,400	$	—	$	250,262	$	195,049	$	—	$	191,449
	Liabilities:
	Series 2012 Notes	$	46,761	$	74,701	$	—	$	172,630	$	277,650	$	—
	May 2015 Notes	149,514		212,529		—		148,253		212,304		—
	February 2018 Notes	270,944		318,135		—		—		—		—
	Term loan	55,921		56,250		—		74,397		75,000		—
	Total	$	523,140	$	661,615	$	—	$	395,280	$	564,954	$	—

Cash_Equivalents_and_Investmen1

Cash Equivalents and Investments (Tables)	3 Months Ended
	Mar. 31, 2014
Cash and Cash Equivalents [Abstract]	'
Summary of cash and available-for-sale securities	'
	Summary of Cash and Available-For-Sale Securities	Adjusted Cost		Unrealized Gains		Unrealized Losses		Estimated Fair Value		Cash and Cash Equivalents		Short-Term Investments
	(In thousands)
	31-Mar-14
	Cash	$	168,984	$	—	$	—	$	168,984	$	168,984	$	—
	Money market funds	165,051		—		—		165,051		165,051		—
	Corporate securities	3,500		58		—		3,558		—		3,558
	Total	$	337,535	$	58	$	—	$	337,593	$	334,035	$	3,558
	31-Dec-13
	Cash	$	8,332	$	—	$	—	$	8,332	$	8,332	$	—
	Money market funds	85,970		—		—		85,970		85,970		—
	Corporate securities	3,500		1,738		—		5,238		—		5,238
	Total	$	97,802	$	1,738	$	—	$	99,540	$	94,302	$	5,238

Foreign_Currency_Hedging_Table

Foreign Currency Hedging (Tables)	3 Months Ended
	Mar. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Schedule of Euro forward contracts	'
	Euro Forward Contracts					March 31, 2014							December 31, 2013
						(In thousands)							(In thousands)
	Currency	Settlement Price		Type		Notional Amount				Fair Value			Notional Amount		Fair Value
		($ per Euro)
	Euro	1.24		Sell Euro		$	10,850			$	(1,197	)	$	10,850	$	(1,207	)
	Euro	1.27		Sell Euro		44,450				(3,710		)	44,450		(3,760		)
	Euro	1.281		Sell Euro		36,814				(2,739		)	36,814		(2,785		)
	Euro	1.3		Sell Euro		—				—			19,500		(1,119		)
	Total					$	92,114			$	(7,646	)	$	111,614	$	(8,871	)
Schedule of location and fair values of Euro contracts in Consolidated Balance Sheets	'
	Cash Flow Hedge	Location		March 31,				December 31,
				2014				2013
	(In thousands)
	Euro contracts	Accrued liabilities		$	7,646			$	7,355
	Euro contracts	Other long-term liabilities		$	—			$	1,516
Schedule of the effect of derivative instruments in the Consolidated Statements of Income and Consolidated Statements of Comprehensive Income	'
		Three Months Ended
		March 31,
		2014				2013
	(In thousands)
	Net gain (loss) recognized in OCI, net of tax (1)	$	67			$	3,568
	Gain (loss) reclassified from accumulated OCI into royalty revenue, net of tax (2)	$	(728	)		$	(1,247	)
	Net gain (loss) recognized in interest and other income, net -- cash flow hedges (3)	$	2			$	3

Intangible_Assets_Tables

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2014
Intangible Assets [Abstract]	'
Schedule of Finite-Lived Intangible Assets [Table Text Block]	'
		March 31, 2014							December 31, 2013
	(in thousands)	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
	Definite lived intangible assets	$	241,314	$	(17,568	)	$	223,746	$	241,314	$	(5,637	)	$	235,677
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	2014 (remaining nine months)	$	25,202
	2015	44,235
	2016	32,661
	2017	18,726
	2018	17,798
	Thereafter	85,124
	Total	$	223,746

Convertible_Notes_Tables

Convertible Notes (Tables)	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Schedule of convertible and non-recourse notes activity	'
				Principal Balance Outstanding				Carrying Value
				March 31,				March 31,		December 31,
	Description	Maturity Date		2014				2014		2013
	(In thousands)
	Convertible Notes
	Series 2012 Notes	February 15, 2015		$	48,311			$	46,761	$	172,630
	May 2015 Notes	May 1, 2015		$	155,250			149,514		148,253
	February 2018 Notes	1-Feb-18		$	300,000			270,944		—
	Term loan	28-Oct-14		$	56,250			55,921		74,397
	Total							$	523,140	$	395,280
Schedule of carrying value and unamortized discount on Series 2012 Notes	'
	(In thousands)	March 31, 2014				December 31, 2013
	Principal amount of the Series 2012 Notes	$	48,311			$	180,000
	Unamortized discount of liability component	(1,550		)		(7,370		)
	Total	$	46,761			$	172,630
Schedule of interest expense on Series 2012 Notes	'
		Three Months Ended
		March 31,
	(In thousands)	2014				2013
	Contractual coupon interest	$	761			$	1,287
	Amortization of debt issuance costs	870				284
	Amortization of debt discount	980				1,487
	Total	$	2,611			$	3,058
Schedule of carrying value and unamortized discount on May 2015 Notes	'
	(In thousands)	March 31, 2014				December 31, 2013
	Principal amount of the May 2015 Notes	$	155,250			$	155,250
	Unamortized discount of liability component	(5,736		)		(6,997		)
	Total	$	149,514			$	148,253
Schedule of interest expense for May 2015 Notes	'
		Three Months Ended
		March 31,
	(In thousands)	2014				2013
	Contractual coupon interest	$	1,455			$	1,455
	Amortization of debt issuance costs	315				304
	Amortization of debt discount	1,261				1,173
	Total	$	3,031			$	2,932
Schedule of carrying value and unamortized discount on February 2018 Notes [Table Text Block]	'
	(In thousands)	March 31, 2014
	Principal amount of the February 2018 Notes	$	300,000
	Unamortized discount of liability component	(29,056		)
	Total	$	270,944
Schedule of interest expense for February 2018 Notes [Table Text Block]	'
		Three Months Ended
		March 31,
	(In thousands)	2014
	Contractual coupon interest	$	1,571
	Amortization of debt issuance costs	222
	Amortization of debt discount	671
	Total	$	2,464

Other_LongTerm_Liabilities_Tab

Other Long-Term Liabilities (Tables)	3 Months Ended
	Mar. 31, 2014
Other Liabilities Disclosure [Abstract]	'
Schedule of other liabilities	'
		March 31,		December 31,
		2014		2013
	(In thousands)
	Accrued lease liability	$	10,700	$	10,700
	Uncertain tax positions	13,346		10,826
	Long-term deferred tax liabilities	10,404		—
	Foreign currency hedge	—		1,516
	Total	$	34,450	$	23,042

Cash_Dividends_Tables

Cash Dividends (Tables)	3 Months Ended
	Mar. 31, 2014
Stockholders' Equity Note [Abstract]	'
Schedule of Conversion Rates for Convertible Notes	'
	Convertible Notes	Conversion Rate per $1,000 Principal Amount	Approximate Conversion Price Per Common Share		Effective Date
	Series 2012 Notes	185.777	$	5.38	March 3, 2014
	May 2015 Notes	162.728	$	6.15	March 3, 2014

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Loss) (Tables)	3 Months Ended
	Mar. 31, 2014
Accumulated Other Comprehensive Income (Loss) [Abstract]	'
Schedule of Accumulated Other Comprehensive Income (Loss)	'
		Unrealized gains (losses) on available-for-sale securities			Unrealized gains (losses) on cash flow hedges			Total Accumulated Other Comprehensive Income (Loss)
	(In thousands)
	Beginning Balance at December 31, 2013	$	1,129		$	(6,017	)	$	(4,888	)
	Activity for the three months ended March 31, 2014	(1,092		)	795			(297		)
	Ending Balance at March 31, 2014	$	37		$	(5,222	)	$	(5,185	)

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Schedule of Revenue by Major Customers) (Details)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Genentech [Member] | Avastin [Member]	'	'
Entity Wide Revenue Major Customer [Line Items]	'	'
Percentage of total revenue (in Percent)	29.00%	36.00%
Genentech [Member] | Herceptin [Member]	'	'
Entity Wide Revenue Major Customer [Line Items]	'	'
Percentage of total revenue (in Percent)	27.00%	33.00%
Genentech [Member] | Lucentis [Member]	'	'
Entity Wide Revenue Major Customer [Line Items]	'	'
Percentage of total revenue (in Percent)	12.00%	13.00%
Elan [Member] | Tysabri [Member]	'	'
Entity Wide Revenue Major Customer [Line Items]	'	'
Percentage of total revenue (in Percent)	9.00%	14.00%
Depomed [Member] | Glumetza [Member]	'	'
Entity Wide Revenue Major Customer [Line Items]	'	'
Percentage of total revenue (in Percent)	17.00%	0.00%

Net_Income_per_Share_Narrative

Net Income per Share (Narrative) (Detail) (USD $)

3 Months Ended

3 Months Ended

3 Months Ended

Mar. 31, 2013

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2013

Aug. 01, 2013

Mar. 31, 2012

Jan. 31, 2012

Feb. 07, 2014

Feb. 06, 2014

Feb. 29, 2012

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Feb. 12, 2014

Mar. 31, 2014

Mar. 31, 2014

Warrants [Member]

Purchased Call Options [Member]

Stock Options [Member]

Stock Options [Member]

Restricted Stock [Member]

February 2015 Notes [Member]

February 2015 Notes [Member]

February 2015 Notes [Member]

Series 2012 Notes [Member]

Series 2012 Notes [Member]

Series 2012 Notes [Member]

May 2015 Notes [Member] [Member]

May 2015 Notes [Member] [Member]

February 2018 Notes [Member]

February 2018 Notes [Member]

February 2018 Notes [Member]

February 2018 Notes [Member]

Warrants [Member]

Purchased Call Options [Member]

Warrants [Member]

Purchased Call Options [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of convertible notes payable

'

'

'

'

'

'

$179,000,000

'

'

'

'

'

'

'

'

'

'

Convertible notes

'

'

'

'

'

$1,000,000

'

$169,000,000

$131,700,000

$131,700,000

$10,000,000

'

'

$270,944,000

$300,000,000

'

'

Antidilutive securities excluded from computation of earnings per share (in Shares)

20,000,000

23,500,000

115,000

139,000

20,000

'

'

'

'

'

'

21,500,000

25,300,000

'

'

29,000,000

32,700,000

Net_Income_per_Share_Net_Incom

Net Income per Share (Net Income Per Basic and Diluted Share) (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Earnings Per Share [Abstract]	'	'
Net income	$72,883	$53,471
Add back interest expense for convertible notes, net of estimated tax of approximately $0 and $3 for the three months ended March 31, 2014 and 2013, respectively	0	6
Income used to compute net income per diluted share	$72,883	$53,477
Total weighted-average shares used to compute net income per basic share (in Shares)	151,198	139,816
Diluted (in Shares)	164,571	149,101
Net income per basic share (in Dollars per Share)	$0.48	$0.38
Net income per diluted share (in Dollars per Share)	$0.44	$0.36
Series 2012 Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Assumed conversion of debt notes (in Shares)	6,903	6,688
May 2015 Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Assumed conversion of debt notes (in Shares)	6,381	2,345
February 2015 Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Assumed conversion of debt notes (in Shares)	0	173
Stock Options [Member]	'	'
Debt Instrument [Line Items]	'	'
Additional shares included in the calculation of diluted EPS (in Shares)	21	18
Restricted Stock [Member]	'	'
Debt Instrument [Line Items]	'	'
Additional shares included in the calculation of diluted EPS (in Shares)	68	61

Net_Income_per_Share_Net_Incom1

Net Income per Share (Net Income Per Basic and Diluted Share) (Parentheticals) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Earnings Per Share [Abstract]	'	'
Estimated tax on interest expense on convertible notes	$0	$3

Fair_Value_Measurements_Narrat

Fair Value Measurements (Narrative) (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Dec. 31, 2013	Apr. 30, 2013
			AxoGen Note Receivable [Member]	AxoGen Note Receivable [Member]	Avinger Note Receivable [Member]
Embedded Derivative, Fair Value of Embedded Derivative Asset	'	'	$1,100,000	$1,100,000	'
Fair value inputs, discount rate (in Percent)	'	'	'	'	19.50%
Period over which revenue is expected for valuation (in years)	'15 years	'	'	'	'
Transfers from level 1 to level 2, amount	0	0	'	'	'
Transfers from level 2 to level 1, amount	$0	$0	'	'	'

Fair_Value_Measurements_Financ

Fair Value Measurements (Financial Instruments Measured at Fair Value on a Recurring Basis) (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Financial assets:	'	'
Assets, Fair Value	$168,609	$91,208
Financial liabilites:	'	'
Foreign currency hedge contracts	7,646	8,871
Money Market Funds [Member]	'	'
Financial assets:	'	'
Cash and Cash Equivalents, Fair Value	165,051	85,970
Equity Securities [Member]	'	'
Financial assets:	'	'
Available for Sale Securities, Fair Value	3,558	5,238
Fair Value Level 1 [Member]	'	'
Financial assets:	'	'
Assets, Fair Value	165,051	85,970
Financial liabilites:	'	'
Foreign currency hedge contracts	0	0
Fair Value Level 1 [Member] | Money Market Funds [Member]	'	'
Financial assets:	'	'
Cash and Cash Equivalents, Fair Value	165,051	85,970
Fair Value Level 1 [Member] | Equity Securities [Member]	'	'
Financial assets:	'	'
Available for Sale Securities, Fair Value	0	0
Fair Value Level 2 [Member]	'	'
Financial assets:	'	'
Assets, Fair Value	3,558	5,238
Financial liabilites:	'	'
Foreign currency hedge contracts	7,646	8,871
Fair Value Level 2 [Member] | Money Market Funds [Member]	'	'
Financial assets:	'	'
Cash and Cash Equivalents, Fair Value	0	0
Fair Value Level 2 [Member] | Equity Securities [Member]	'	'
Financial assets:	'	'
Available for Sale Securities, Fair Value	$3,558	$5,238

Fair_Value_Measurements_Schedu

Fair Value Measurements (Schedule of Fair Value of Assets and Liabilities not Subject to Fair Value Recognition) (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Assets	'	'
Notes receivable, Carrying Value	$248,400,000	$195,049,000
Liabilities:	'	'
Convertible Notes Payable, Carrying Value	523,140,000	395,280,000
Series 2012 Notes [Member]	'	'
Liabilities:	'	'
Convertible Notes Payable, Carrying Value	46,761,000	172,630,000
May 2015 Notes [Member]	'	'
Liabilities:	'	'
Convertible Notes Payable, Carrying Value	149,514,000	148,253,000
February 2018 Notes [Member]	'	'
Liabilities:	'	'
Convertible Notes Payable, Carrying Value	270,944,000	0
Term Loan. [Member]	'	'
Liabilities:	'	'
Convertible Notes Payable, Carrying Value	55,921,000	74,397,000
Wellstat Note Receivable [Member]	'	'
Assets	'	'
Notes receivable, Carrying Value	50,191,000	47,694,000
AxoGen Note Receivable [Member]	'	'
Fair Value by Balance Sheet Grouping [Line Items]	'	'
Embedded Derivative, Fair Value of Embedded Derivative Asset	1,100,000	1,100,000
Assets	'	'
Notes receivable, Carrying Value	27,673,000	26,544,000
Avinger Note Receivable [Member]	'	'
Assets	'	'
Notes receivable, Carrying Value	20,336,000	20,250,000
LENSAR Note Receivable [Member]	'	'
Assets	'	'
Notes receivable, Carrying Value	39,581,000	39,572,000
Durata Note Receivable [Member]	'	'
Assets	'	'
Notes receivable, Carrying Value	25,000,000	24,995,000
Direct Flow Medical Note Receivable [Member]	'	'
Assets	'	'
Notes receivable, Carrying Value	34,926,000	34,799,000
Paradigm Spine [Member]	'	'
Assets	'	'
Notes receivable, Carrying Value	49,493,000	0
Hyperion [Member]	'	'
Assets	'	'
Notes receivable, Carrying Value	1,200,000	1,195,000
Fair Value Level 2 [Member]	'	'
Liabilities:	'	'
Notes payable, Fair Value	661,615,000	564,954,000
Fair Value Level 2 [Member] | Series 2012 Notes [Member]	'	'
Liabilities:	'	'
Notes payable, Fair Value	74,701,000	277,650,000
Fair Value Level 2 [Member] | May 2015 Notes [Member]	'	'
Liabilities:	'	'
Notes payable, Fair Value	212,529,000	212,304,000
Fair Value Level 2 [Member] | February 2018 Notes [Member]	'	'
Liabilities:	'	'
Notes payable, Fair Value	318,135,000	'
Fair Value Level 2 [Member] | Term Loan. [Member]	'	'
Liabilities:	'	'
Notes payable, Fair Value	56,250,000	75,000,000
Fair Value Level 2 [Member] | LENSAR Note Receivable [Member]	'	'
Assets	'	'
Notes receivable, Carrying Value	0	0
Fair Value Level 2 [Member] | Durata Note Receivable [Member]	'	'
Assets	'	'
Notes receivable, Carrying Value	0	0
Fair Value Level 2 [Member] | Direct Flow Medical Note Receivable [Member]	'	'
Assets	'	'
Notes receivable, Carrying Value	0	0
Fair Value Level 2 [Member] | Paradigm Spine [Member]	'	'
Assets	'	'
Notes receivable, Carrying Value	0	0
Fair Value Level 2 [Member] | Hyperion [Member]	'	'
Assets	'	'
Notes receivable, Fair Value	0	0
Fair Value Level 3 [Member]	'	'
Assets	'	'
Notes receivable, Fair Value	250,262,000	191,449,000
Fair Value Level 3 [Member] | Wellstat Note Receivable [Member]	'	'
Assets	'	'
Notes receivable, Fair Value	52,194,000	46,042,000
Fair Value Level 3 [Member] | AxoGen Note Receivable [Member]	'	'
Assets	'	'
Notes receivable, Fair Value	26,361,000	25,785,000
Fair Value Level 3 [Member] | Avinger Note Receivable [Member]	'	'
Assets	'	'
Notes receivable, Fair Value	20,155,000	19,061,000
Fair Value Level 3 [Member] | LENSAR Note Receivable [Member]	'	'
Assets	'	'
Notes receivable, Carrying Value	40,000,000	39,572,000
Fair Value Level 3 [Member] | Durata Note Receivable [Member]	'	'
Assets	'	'
Notes receivable, Carrying Value	25,000,000	24,995,000
Fair Value Level 3 [Member] | Direct Flow Medical Note Receivable [Member]	'	'
Assets	'	'
Notes receivable, Carrying Value	35,859,000	34,799,000
Fair Value Level 3 [Member] | Paradigm Spine [Member]	'	'
Assets	'	'
Notes receivable, Carrying Value	49,493,000	0
Fair Value Level 3 [Member] | Hyperion [Member]	'	'
Assets	'	'
Notes receivable, Fair Value	$1,200,000	$1,195,000

Cash_Equivalents_and_Investmen2

Cash Equivalents and Investments (Narrative) (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Cash and Cash Equivalents [Abstract]	'	'
Gains (losses) on sales of available-for-sale securities	$0	$0

Cash_Equivalents_and_Investmen3

Cash Equivalents and Investments (Summary of Cash and Available-For-Sale Securities) (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014		Dec. 31, 2013		Mar. 31, 2013	Dec. 31, 2012
Schedule of Available-For-Sale Securities [Line Items]	'		'		'	'
Adjusted Cost	$337,535		$97,802		'	'
Unrealized Gains	58		1,738		'	'
Unrealized Losses	0		0		'	'
Cash, Cash Equivalents and Available-for-Sale Securities, Fair Value	337,593		99,540		'	'
Cash and Cash Equivalents	334,035	[1]	94,302	[2]	182,192	131,212
Short-Term Marketable Securities	3,558	[1]	5,238	[2]	'	'
Cash [Member]	'		'		'	'
Schedule of Available-For-Sale Securities [Line Items]	'		'		'	'
Adjusted Cost	168,984		8,332		'	'
Unrealized Gains	0		0		'	'
Unrealized Losses	0		0		'	'
Cash, Cash Equivalents and Available-for-Sale Securities, Fair Value	168,984		8,332		'	'
Cash and Cash Equivalents	168,984		8,332		'	'
Short-Term Marketable Securities	0		0		'	'
Money Market Funds [Member]	'		'		'	'
Schedule of Available-For-Sale Securities [Line Items]	'		'		'	'
Adjusted Cost	165,051		85,970		'	'
Unrealized Gains	0		0		'	'
Unrealized Losses	0		0		'	'
Cash, Cash Equivalents and Available-for-Sale Securities, Fair Value	165,051		85,970		'	'
Cash and Cash Equivalents	165,051		85,970		'	'
Short-Term Marketable Securities	0		0		'	'
Equity Securities [Member]	'		'		'	'
Schedule of Available-For-Sale Securities [Line Items]	'		'		'	'
Adjusted Cost	3,500		3,500		'	'
Unrealized Gains	58		1,738		'	'
Unrealized Losses	0		0		'	'
Cash, Cash Equivalents and Available-for-Sale Securities, Fair Value	3,558		5,238		'	'
Cash and Cash Equivalents	0		0		'	'
Short-Term Marketable Securities	$3,558		$5,238		'	'
[1]	unaudited
[2]	Note 1

Foreign_Currency_Hedging_Narra

Foreign Currency Hedging (Narrative) (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Derivative Instrument Gain Loss [Line Items]	'	'
Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net	($2)	($3)
Restructuring hedges, net loss	$0	$0

Foreign_Currency_Hedging_Sched

Foreign Currency Hedging (Schedule of Foreign Currency Exchange Contracts Designated as Cash Flow Hedges) (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Derivative [Line Items]	'	'
Fair Value	($7,646)	($8,871)
Derivative, Notional Amount	92,114	111,614
Eurodollar Sell Forward Contract 1.240 [Member]	'	'
Derivative [Line Items]	'	'
Derivative, Forward Exchange Rate	1.24	'
Eurodollar Sell Forward Contract 1.270 [Member]	'	'
Derivative [Line Items]	'	'
Derivative, Forward Exchange Rate	1.27	'
Eurodollar Sell Forward Contract 1.281 [Member]	'	'
Derivative [Line Items]	'	'
Derivative, Forward Exchange Rate	1.281	'
Eurodollar Sell Forward Contract 1.300 [Member]	'	'
Derivative [Line Items]	'	'
Derivative, Forward Exchange Rate	1.3	'
Euro Forward Contracts [Member] | Eurodollar Sell Forward Contract 1.240 [Member]	'	'
Derivative [Line Items]	'	'
Fair Value	-1,197	-1,207
Derivative, Notional Amount	10,850	10,850
Euro Forward Contracts [Member] | Eurodollar Sell Forward Contract 1.270 [Member]	'	'
Derivative [Line Items]	'	'
Fair Value	-3,710	-3,760
Derivative, Notional Amount	44,450	44,450
Euro Forward Contracts [Member] | Eurodollar Sell Forward Contract 1.281 [Member]	'	'
Derivative [Line Items]	'	'
Fair Value	-2,739	-2,785
Derivative, Notional Amount	36,814	36,814
Euro Forward Contracts [Member] | Eurodollar Sell Forward Contract 1.300 [Member]	'	'
Derivative [Line Items]	'	'
Fair Value	0	-1,119
Derivative, Notional Amount	$0	$19,500

Foreign_Currency_Hedging_Fair_

Foreign Currency Hedging (Fair Value of Foreign Currency Exchange Contracts on Condensed Consolidated Balance Sheet) (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'	'
Euro contracts, Accrued liabilities	$7,646	$7,355
Euro contracts, Other long-term liabilities	$0	$1,516

Foreign_Currency_Hedging_Sched1

Foreign Currency Hedging (Schedule of Effect of Derivative Instruments in Consolidated Statements of Income and Consolidated Statements of Comprehensive Income) (Detail) (Cash Flow Hedges [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014		Mar. 31, 2013
Cash Flow Hedges [Member]	'		'
Derivative [Line Items]	'		'
Net gain (loss) recognized in OCI, net of tax	$67	[1]	$3,568	[1]
Gain (loss) reclassified from accumulated OCI into royalty revenue, net of tax	-728	[2]	-1,247	[2]
Net gain (loss) recognized in interest and other income, net	$2	[3]	$3	[3]
[1]	Net change in the fair value of the effective portion of cash flow hedges classified in OCI.
[2]	Effective portion classified as royalty revenue.
[3]	Ineffectiveness from excess hedge was approximately ($2) and ($3) for the three months ended March 31, 2014 and 2013, respectively. Net loss from restructuring hedges was zero for the three months ended March 31, 2014 and 2013.

Notes_Receivable_and_Other_Lon1

Notes Receivable and Other Long-term Receivables (Narrative) (Detail) (USD $)

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

3 Months Ended

1 Months Ended

1 Months Ended

3 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

0 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

58 Months Ended

0 Months Ended

3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Feb. 06, 2014

Oct. 31, 2013

Mar. 31, 2014

Aug. 15, 2013

Jul. 31, 2012

Mar. 31, 2014

Dec. 31, 2012

Sep. 24, 2013

Sep. 30, 2013

Mar. 31, 2014

Aug. 14, 2013

Oct. 03, 2013

Nov. 02, 2013

Oct. 31, 2013

Nov. 05, 2013

Nov. 06, 2013

Mar. 31, 2014

Feb. 14, 2014

Mar. 05, 2014

Mar. 05, 2013

Jan. 27, 2012

Mar. 31, 2012

Mar. 31, 2014

Aug. 31, 2012

Jul. 31, 2012

Apr. 30, 2013

Jun. 30, 2014

Apr. 18, 2013

Aug. 15, 2013

Feb. 28, 2013

Jan. 31, 2013

Mar. 31, 2014

Nov. 02, 2012

Jul. 31, 2012

Aug. 15, 2013

Mar. 31, 2014

Jun. 28, 2013

Mar. 31, 2014

Apr. 18, 2013

Oct. 03, 2013

Oct. 31, 2012

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Apr. 30, 2018

Aug. 15, 2013

Aug. 15, 2013

Oct. 31, 2013

Nov. 06, 2013

Mar. 31, 2014

Oct. 31, 2013

Wellstat Diagnostics [Member]

Wellstat Diagnostics [Member]

Merus Labs [Member]

Merus Labs [Member]

Merus Labs [Member]

Merus Labs [Member]

AxoGen [Member]

AxoGen [Member]

AxoGen [Member]

LENSAR [Member]

Durata [Member]

Durata [Member]

DirectFlow [Member]

DirectFlow [Member]

Paradigm Spine [Member]

Paradigm Spine [Member]

Hyperion [Member]

Hyperion [Member]

Hyperion [Member]

Notes Receivable [Member]

Notes Receivable [Member]

Notes Receivable [Member]

Notes Receivable [Member]

Notes Receivable [Member]

Notes Receivable [Member]

Notes Receivable [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Initial Loan [Member]

Initial Loan [Member]

Additional Loan [Member]

Additional Loan [Member]

Additional Loan [Member]

Additional Loan [Member]

Royalty Agreement [Member]

Royalty Agreement [Member]

Royalty Agreement [Member]

Royalty Agreement [Member]

Royalty Agreement [Member]

Term loan and interest [Member]

Forbearance principal and interest [Member]

Tranche two [Member]

Tranche two [Member]

Tranche two [Member]

Tranche three [Member]

Wellstat Diagnostics [Member]

Wellstat Diagnostics [Member]

Wellstat Diagnostics [Member]

Merus Labs [Member]

Avinger [Member]

Avinger [Member]

Avinger [Member]

Wellstat Diagnostics [Member]

Wellstat Diagnostics [Member]

Wellstat Diagnostics [Member]

Wellstat Diagnostics [Member]

Wellstat Diagnostics [Member]

Merus Labs [Member]

Wellstat Diagnostics [Member]

Merus Labs [Member]

Wellstat Diagnostics [Member]

Merus Labs [Member]

Avinger [Member]

LENSAR [Member]

AxoGen [Member]

AxoGen [Member]

AxoGen [Member]

AxoGen [Member]

Avinger [Member]

Wellstat Diagnostics [Member]

Wellstat Diagnostics [Member]

Durata [Member]

DirectFlow [Member]

Paradigm Spine [Member]

Durata [Member]

Accounts Notes And Loans Receivable [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Financing receivable, gross

'

'

'

'

'

'

'

$0

'

'

'

'

'

$40,000,000

'

$25,000,000

'

$35,000,000

'

$50,000,000

'

'

$2,300,000

$7,500,000

$50,200,000

$10,000,000

$35,000,000

'

'

$20,000,000

'

'

'

'

$40,000,000

'

'

'

$1,300,000

'

'

'

'

'

'

'

'

'

'

$15,000,000

$15,000,000

'

$30,000,000

Number of payments to be received

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Periodic contractual payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

First minimum payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Second minimum payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Financing Receivable, Modifications, Pre-Modification Recorded Investment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

33,700,000

'

'

'

'

'

'

'

'

'

'

1,300,000

9,100,000

'

'

'

'

Financing receivable, modification, cost as a component of interest and other income, net

'

'

'

'

'

2,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term of receivable (in Duration)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'8 years

'

'

'

'

'

'

'

'

'

'

Royalty rate on AxoGen net revenues (in percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9.95%

'

'

'

'

'

'

'

'

'

'

Guaranteed quarterly minimum payment-low

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.3

'

'

'

'

'

'

'

'

'

'

Guaranteed quarterly minimum payment-high

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,300,000

'

'

'

'

'

'

'

'

'

'

Interest rate of note receivable (in Percent)

'

'

'

'

'

5.00%

'

'

'

'

'

'

'

15.50%

'

14.00%

'

15.50%

'

13.00%

'

'

'

10.00%

'

12.00%

'

'

'

12.00%

'

'

'

'

'

'

'

13.50%

'

14.00%

14.00%

'

'

'

'

'

'

'

'

12.75%

13.50%

'

'

Reduction in royalty rate (in percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

'

Repayment of notes receivable

0

9,279,000

'

'

'

'

'

7,500,000

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Financing receivable, prepayment fee

'

'

'

'

'

'

'

'

'

0.01

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Credit agreement, stated interest rate (in Percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds received under remedies available for borrower's breach of terms credit agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount company has agreed to advance under agreement

'

'

'

'

'

'

55,000,000

'

'

'

'

'

'

60,000,000

70,000,000

'

50,000,000

'

75,000,000

'

'

'

'

'

'

'

'

40,000,000

'

'

'

7,900,000

'

8,700,000

'

'

'

'

'

'

'

20,000,000

'

'

'

'

'

'

'

'

'

12,500,000

'

Financing Receivable, Modifications, Post-Modification Recorded Investment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

44,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Forbearance period under terms of credit agreement (in Duration)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'120 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Letter of credit extended

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term of royalty agreement (in Duration)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'8 years

'

'

'

'

'

'

'

'

'

'

Total consideration paid to AxoGen for the royalty rights

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,800,000

'

'

'

'

'

'

'

'

'

'

Initial interim funding for royalty rights

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,800,000

'

'

'

'

'

'

'

'

'

'

Internal rate of return (in percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

32.50%

'

'

'

'

'

'

'

'

'

'

fair value change of control

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,100,000

'

1,100,000

'

'

'

'

'

'

'

Embedded Derivative, Gain (Loss) on Embedded Derivative, Net

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

0

'

'

'

'

'

'

'

'

Investment Owned, Balance, Shares

'

'

'

'

'

'

'

'

'

'

'

'

1,166,666

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share Price

'

'

$7.97

'

'

'

'

'

'

'

'

'

$3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Investment Owned, at Cost

'

'

'

'

'

'

'

'

'

'

'

'

3,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Investment Owned, at Fair Value

'

'

'

'

'

'

'

'

'

'

'

3,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrealized Gain (Loss) on Investments

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum amount of additional funds, upon attainment of milestones

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum amount of additional funds, upon attainment of milestones

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Date of First Required Payment

'

'

'

'

'

'

'

'

'

'

'

'

'

31-Dec-16

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period after occurence of milestone, additional funding available [months]

'

'

'

'9 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Low end of amount company has agreed to advance under credit agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of collateral supporting note receivable

'

'

'

'

$52,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	0 Months Ended	3 Months Ended
	Oct. 17, 2013	Mar. 31, 2014	Dec. 31, 2013	Oct. 18, 2013
Finite-Lived Intangible Assets [Line Items]	'	'	'	'
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	'	$25,202,000	'	'
Finite-Lived Intangible Assets, Gross	'	241,314,000	241,314,000	'
Finite-Lived Intangible Assets, Accumulated Amortization	'	-17,568,000	-5,637,000	'
Intangible purchase price not being amortized	'	73,100,000	76,800,000	'
Finite-Lived Intangible Asset, Useful Life	'	'9 years	'	'
Finite-Lived Intangible Assets, Net	'	223,746,000	235,677,000	'
Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount	'	223,700,000	'	'
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	'	'7 years 9 months	'	'
Finite-Lived Intangible Assets, Amortization Expense, Year Two	'	44,235,000	'	'
Finite-Lived Intangible Assets, Amortization Expense, Year Three	'	32,661,000	'	'
Finite-Lived Intangible Assets, Amortization Expense, Year Four	'	18,726,000	'	'
Finite-Lived Intangible Assets, Amortization Expense, Year Five	'	17,798,000	'	'
Finite-Lived Intangible Assets, Amortization Expense, after Year Five	'	85,124,000	'	'
Payments to Acquire Intangible Assets	240,500,000	'	'	'
Total consideration paid to purchase intangible assets, plus transaction costs	'	'	'	241,300,000
Business Acquisition, Transaction Costs	'	'	'	800,000
Glumetza [Member]	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'
Intangible purchase price being amortized	'	'	'	164,500,000
Janumet XR [Member]	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'
Intangible purchase price being amortized	'	'	'	$3,700,000

Accrued_Liabilities_Accrued_Li

Accrued Liabilities (Accrued Liabilities) (Detail) (USD $)	Mar. 31, 2014		Dec. 31, 2013
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]	'		'
Compensation	$1,314		$768
Interest	4,175		2,925
Foreign currency hedge	7,646		7,355
Dividend payable	72,243		59
Legal	814		324
Other	838		426
Total	$87,030	[1]	$11,857	[2]
[1]	unaudited
[2]	Note 1

Commitments_and_Contingencies_

Commitments and Contingencies (Narrative) (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'	'
Retroactive royalty rate on past U.S.-based sales to be paid by Genentech (in Percent)	2.13%	'
Total lease payments for the duration of the guarantee	$87,400,000	'
Accrued lease liability	$10,700,000	$10,700,000

Convertible_Notes_Narrative_De

Convertible Notes (Narrative) (Detail) (USD $)

3 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

0 Months Ended

Share data in Millions, except Per Share data, unless otherwise specified

Mar. 31, 2014

Mar. 31, 2013

Jun. 30, 2014

Feb. 06, 2014

16-May-11

Feb. 05, 2014

Jan. 31, 2012

Mar. 31, 2014

Jun. 30, 2013

Feb. 12, 2014

Feb. 07, 2014

Feb. 06, 2014

Dec. 31, 2013

Aug. 01, 2013

Feb. 29, 2012

16-May-11

Mar. 31, 2014

Jun. 30, 2013

Dec. 31, 2013

Mar. 31, 2014

Jan. 31, 2013

Mar. 31, 2014

Jan. 31, 2012

Mar. 31, 2014

Aug. 01, 2013

Feb. 11, 2014

Mar. 31, 2014

Feb. 12, 2014

Feb. 11, 2014

Mar. 31, 2014

Feb. 05, 2014

Mar. 31, 2014

Mar. 31, 2014

Oct. 28, 2013

Mar. 31, 2014

Oct. 28, 2013

Series 2012 Notes [Member]

Series 2012 Notes [Member]

Series 2012 Notes [Member]

Series 2012 Notes [Member]

Series 2012 Notes [Member]

Series 2012 Notes [Member]

Series 2012 Notes [Member]

Series 2012 Notes [Member]

Series 2012 Notes [Member]

Series 2012 Notes [Member]

May 2015 Notes [Member]

May 2015 Notes [Member]

May 2015 Notes [Member]

May 2015 Notes [Member]

Purchased Call Options [Member]

Warrants [Member]

Warrants [Member]

February 2015 Notes [Member]

February 2015 Notes [Member]

February 2015 Notes [Member]

February 2018 Notes [Member]

February 2018 Notes [Member]

February 2018 Notes [Member]

February 2018 Note Purchase Call Option [Member]

February 2018 Note Purchase Call Option [Member]

February 2018 Note Warrant [Member]

February 2018 Note Warrant [Member]

Term Loan. [Member]

Term Loan. [Member]

Term Loan. [Member]

Term Loan. [Member]

Base Rate [Member]

Base Rate [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible notes

'

'

'

'

'

'

'

'

'

'

$131,700,000

$131,700,000

'

'

$10,000,000

$155,300,000

'

'

'

'

'

'

$169,000,000

'

$1,000,000

'

$270,944,000

$300,000,000

'

'

'

'

'

'

'

'

Total consideration given for convertible note exchange

'

'

'

'

'

'

'

'

'

'

'

191,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Incentive fee per each $1,000 principal amount tendered to convert debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal amount a $5 incentive cash payment per each to convert debt

1,000

'

'

'

'

'

1,000

1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Induced conversion of convertible debt expense

'

'

'

'

'

'

845,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred issue costs, incentive payment allocated

'

'

'

'

'

'

765,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Adjustments to additional paid in capital, equity component of convertible debt

'

'

'

'

'

'

52,000

10,900,000

'

'

'

'

'

'

'

'

12,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Noted obligation allocated to deferred tax assets

'

'

'

'

'

'

28,000

5,900,000

'

'

'

'

'

'

'

'

6,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, interest rate (in Percent)

'

'

'

'

'

'

2.88%

'

'

'

'

'

'

'

'

'

3.75%

'

'

'

'

'

'

'

'

'

'

4.00%

'

'

'

'

'

'

2.24%

1.00%

Convertible note rate conversion trading days (in days)

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Notes rate conversion consecutive trading days (in days)

30

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible notes due upon demand within (in years)

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total debt discount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

18,900,000

'

'

'

'

'

'

16,800,000

'

'

'

'

'

'

'

'

'

'

'

'

Unamortized discount of liability component

'

'

'

'

'

'

-2,300,000

-1,550,000

'

-2,100,000

'

'

-7,370,000

'

'

'

-5,736,000

'

-6,997,000

'

'

'

'

'

'

'

-29,056,000

-29,700,000

'

'

'

'

'

'

'

'

Debt discount recorded to additional paid in capital

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

19,300,000

'

'

'

'

'

'

'

'

Debt discount recorded to deferred tax liability

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,400,000

'

'

'

'

'

'

'

'

Minimum conversion price percent for note conversion (in Percent)

'

'

'

'

'

'

130.00%

'

'

'

'

'

'

'

'

'

130.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Notes rate conversion business day period (in days)

5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Notes rate conversion consecutive trading day period (in days)

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum percent of common stock closing price and conversion rate to convert note (in Percent)

'

'

'

'

'

'

98.00%

'

'

'

'

'

'

'

'

'

98.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Effective Percentage

'

'

'

'

7.50%

'

7.30%

7.30%

'

'

'

'

'

'

'

7.50%

'

'

'

'

'

'

'

'

'

'

'

6.90%

'

'

'

'

'

'

'

'

Convertible notes, conversion price (in Dollars per Share)

'

'

'

'

'

'

'

$5.38

'

'

'

'

'

'

'

'

$6.15

'

'

'

'

$7.23

'

'

'

'

'

$9.17

'

'

'

$10.36

'

'

'

'

Estimated market interest rate for similar nonconvertible instrument

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7.00%

'

'

'

'

'

'

'

'

Debt instrument, convertible, remaining amortization period (in Duration)

'

'

'

'

'

'

'

'10 months 21 days

'

'

'

'

'

'

'

'

'1 year 1 month 1 day

'

'

'

'

'

'

'

'

'

'46 months

'

'

'

'

'

'

'

'

'

Debt instrument, convertible, conversion threshold (in Dollars per Share)

'

'

'

'

'

'

'

$7

$7.12

'

'

'

'

'

'

'

$7.99

$8.13

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, convertible, if-converted value

'

'

'

'

'

'

'

26,300,000

'

'

'

'

'

'

'

'

54,700,000

'

'

'

'

'

'

'

'

'

28,000,000

'

'

'

'

'

'

'

'

'

Net proceeds from the issuance of convertible notes

300,000,000

0

'

'

'

'

'

'

'

'

'

'

'

'

'

149,700,000

'

'

'

'

'

'

'

'

'

290,200,000

'

'

'

'

'

'

'

'

'

'

Convertible notes repurchase price as a percentage of principal (in Percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Face Amount

'

'

'

'

'

'

'

48,311,000

'

'

'

48,300,000

180,000,000

180,000,000

'

'

155,250,000

'

155,250,000

'

'

'

'

0

'

'

300,000,000

300,000,000

'

'

'

'

56,250,000

'

'

'

Conversion Rate per $1,000 Principal Amount (in Ratio)

'

'

'

'

'

'

'

185.777

'

'

'

'

'

'

'

'

162.728

'

'

'

'

'

'

'

'

109.1048

'

'

'

'

'

'

'

'

'

'

Number of hedge counterparties (in Counterparties)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

Purchased call options cost

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,800,000

'

'

'

'

'

'

'

'

31,000,000

'

'

'

'

'

'

'

Number of shares of common stock covered by the purchased call options purchased (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25.3

'

27.5

'

'

'

'

'

'

'

32.7

'

'

'

'

'

'

Proceeds from Issuance of Warrants

11,427,000

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,900,000

10,900,000

'

'

'

'

'

'

'

'

11,400,000

'

'

'

'

'

Debt conversion, shares issued (in Shares)

'

'

'

'

'

20.3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Conversion, Converted Instrument, Amount

'

'

'

'

'

157,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash paid to exchange convertible note

'

'

'

'

'

'

'

'

'

'

'

34,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Inducement fee

'

'

'

'

'

'

'

'

'

'

'

2,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest Payable

'

'

'

'

'

'

'

'

'

'

'

1,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred Income Tax Expense (Benefit)

'

'

'

'

'

29,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred taxes included in purchased call options cost

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,200,000

'

'

'

'

'

'

'

'

10,800,000

'

'

'

'

'

'

'

Gain on conversion of convertible notes

6,143,000

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt discount, derecognition on exchange

'

'

'

'

'

'

'

'

'

'

'

5,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Exchange cost other

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share Price

'

'

'

$7.97

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividends Payable, Amount Per Share

$0.15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Short-term Debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$75,000,000

'

'

Convertible_Notes_Summary_of_C

Convertible Notes (Summary of Convertible Notes) (Detail) (USD $)

3 Months Ended

1 Months Ended

3 Months Ended

3 Months Ended

1 Months Ended

0 Months Ended

3 Months Ended

3 Months Ended

Mar. 31, 2014

Dec. 31, 2013

Jan. 31, 2012

Mar. 31, 2014

Feb. 06, 2014

Dec. 31, 2013

Aug. 01, 2013

Mar. 31, 2014

Dec. 31, 2013

Jan. 31, 2012

Mar. 31, 2014

Feb. 11, 2014

Mar. 31, 2014

Feb. 12, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Series 2012 Notes [Member]

Series 2012 Notes [Member]

Series 2012 Notes [Member]

Series 2012 Notes [Member]

Series 2012 Notes [Member]

May 2015 Notes [Member]

May 2015 Notes [Member]

February 2015 Notes [Member]

February 2015 Notes [Member]

February 2018 Notes [Member]

February 2018 Notes [Member]

February 2018 Notes [Member]

February 2018 Notes [Member]

Term Loan. [Member]

Term Loan. [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

2.88%

'

'

'

'

3.75%

'

'

'

'

'

4.00%

'

'

'

Debt Instrument, Convertible, Conversion Ratio

'

'

'

185.777

'

'

'

162.728

'

'

'

109.1048

'

'

'

'

'

Convertible notes, conversion price (in Dollars per Share)

'

'

'

$5.38

'

'

'

$6.15

'

'

'

'

'

$9.17

'

'

'

Principal amount a $5 incentive cash payment per each to convert debt

$1,000

'

$1,000

$1,000

'

'

'

'

'

$1,000

'

'

'

'

'

'

'

Convertible Notes, Maturity Date (Date)

'

'

'

15-Feb-15

'

'

'

1-May-15

'

'

'

'

1-Feb-18

'

'

28-Oct-14

'

Convertible Notes, Principal Balance Outstanding

'

'

'

48,311,000

48,300,000

180,000,000

180,000,000

155,250,000

155,250,000

'

0

'

300,000,000

300,000,000

'

56,250,000

'

Term loan payable

55,921,000

[1]

74,397,000

[1]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Notes Payable, Carrying Value

$523,140,000

$395,280,000

'

$46,761,000

'

$172,630,000

'

$149,514,000

$148,253,000

'

'

'

$270,944,000

'

$0

$55,921,000

$74,397,000

[1]

unaudited

Convertible_Notes_Summary_of_S

Convertible Notes (Summary of Series 2012 Notes) (Detail) (USD $)	Mar. 31, 2014	Feb. 12, 2014	Feb. 06, 2014	Dec. 31, 2013	Aug. 01, 2013	Jan. 31, 2012
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'	'	'	'	'	'
Convertible Notes Payable, Carrying Value	$523,140	'	'	$395,280	'	'
Series 2012 Notes [Member]	'	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'	'
Convertible Notes, Principal Balance Outstanding	48,311	'	48,300	180,000	180,000	'
Unamortized discount of liability component	-1,550	-2,100	'	-7,370	'	-2,300
Convertible Notes Payable, Carrying Value	$46,761	'	'	$172,630	'	'

Convertible_Notes_Interest_Exp

Convertible Notes (Interest Expense for the Series 2012 Notes) (Detail) (Series 2012 Notes [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Series 2012 Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Contractual coupon interest	$761	$1,287
Amortization of debt issuance costs	870	284
Amortization of debt discount	980	1,487
Total	$2,611	$3,058

Convertible_Notes_Summary_of_M

Convertible Notes (Summary of May 2015 Notes) (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'	'
Convertible Notes Payable, Carrying Value	$523,140	$395,280
May 2015 Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Face Amount	155,250	155,250
Unamortized discount of liability component	-5,736	-6,997
Convertible Notes Payable, Carrying Value	$149,514	$148,253

Convertible_Notes_Interest_Exp1

Convertible Notes (Interest Expense for the May 2015 Notes) (Detail) (May 2015 Notes [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
May 2015 Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Contractual coupon interest	$1,455	$1,455
Amortization of debt issuance costs	315	304
Amortization of debt discount	1,261	1,173
Total	$3,031	$2,932

Convertible_Notes_Convertible_

Convertible Notes Convertible Notes (Summary of February 2018 Notes) (Detail) (Details) (February 2018 Notes [Member], USD $)	Mar. 31, 2014	Feb. 12, 2014
In Thousands, unless otherwise specified
February 2018 Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Unamortized Discount	($29,056)	($29,700)
Convertible notes	270,944	300,000
Debt Instrument, Face Amount	$300,000	$300,000

Convertible_Notes_Convertible_1

Convertible Notes Convertible Notes (Interest Expense for February 2018 Notes) (Detail) (Details) (February 2018 Notes [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
February 2018 Notes [Member]	'
Debt Instrument [Line Items]	'
Contractual coupon interest	$1,571
Amortization of debt issuance costs	222
Amortization of debt discount	671
Total	$2,464

Other_LongTerm_Liabilities_Oth

Other Long-Term Liabilities (Other Long-Term Liabilities) (Detail) (USD $)	Mar. 31, 2014		Dec. 31, 2013
In Thousands, unless otherwise specified
Other Liabilities Disclosure [Abstract]	'		'
Accrued lease liability	$10,700		$10,700
Uncertain tax position	13,346		10,826
Long-term Deferred Tax Liabilities	10,404		0
Foreign currency hedge, long-term	0		1,516
Total	$34,450	[1]	$23,042	[2]
[1]	unaudited
[2]	Note 1

StockBased_Compensation_Summar

Stock-Based Compensation (Summary of Stock Option and Restricted Stock Award Activity) (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014
Stock-Based Incentive Plan [Member]	'
Share Based Compensation Arrangment By Share Based Payment Award [Line Items]	'
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures	-36
Shares Available for Grant, Balance beginning of period (in Shares)	4,478
Shares Available for Grant, Balance end of period (in Shares)	4,442
Stock Options [Member]	'
Share Based Compensation Arrangment By Share Based Payment Award [Line Items]	'
Stock Options, Number of Shares, Balance at beginning of period (in Shares)	172
Stock Options, Number of Shares Granted (in Shares)	0
Stock Options, Number of Shares, Balance at end of period (in Shares)	172
Stock Options, Weighted Average Exercise Price, Balance at beginning of period (in Dollars per Share)	16.52
Stock Options, Weighted Average Exercise Price, Balance at end of period (in Dollars per Share)	16.52
Restricted Stock [Member]	'
Share Based Compensation Arrangment By Share Based Payment Award [Line Items]	'
Restricted Stock Award, Number of Shares, Balance at beginning of period (in Shares)	114
Restricted Stock Awards, Number of Shares Granted (in Shares)	36
Restricted Stock Awards, Number of Shares, Balance at end of period (in Shares)	150
Restricted Stock Awards, Weighted Average Grant-date Fair Value, Balance at beginning of period (in Dollars per Share)	7.45
Restricted Stock Awards, Weighted Average Grant-date Fair Value, Granted (in Dollars per Share)	8.4
Restricted Stock Awards, Weighted Average Grant-date Fair Value, Balance at end of period (in Dollars per Share)	7.68

Cash_Dividends_Narrative_Detai

Cash Dividends (Narrative) (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014
Stockholders' Equity Note [Abstract]	'
Dividends payable quarterly (in Dollars per Share)	$0.15
Dividends payable, date declared (Date)	29-Jan-14

Cash_Dividends_Summary_of_Conv

Cash Dividends (Summary of Conversion Rates for Convertible Notes) (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014
Series 2012 Notes [Member]	'
Debt Instrument [Line Items]	'
Conversion Rate per $1,000 Principal Amount (in Ratio)	185.777
Approximate Conversion Price Per Common Share (in Dollars per Share)	$5.38
Effective Date (Date)	3-Mar-14
May 2015 Notes [Member]	'
Debt Instrument [Line Items]	'
Conversion Rate per $1,000 Principal Amount (in Ratio)	162.728
Approximate Conversion Price Per Common Share (in Dollars per Share)	$6.15
Effective Date (Date)	3-Mar-14

Income_Taxes_Narrative_Detail

Income Taxes (Narrative) (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'	'	'
Federal statutory income tax rate (in Percent)	'	'	35.00%
Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions	'	'	$2.40
Release of tax reserve against federal tax credits taken in prior years	$3.90	$6.50	'

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Loss) (Schedule of Balances of Accumulated Other Comprehensive Income (Loss)) (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014		Mar. 31, 2013
Accumulated Other Comprehensive Income (Loss) [Abstract]	'		'
Unrealized gains (losses) on available-for-sale securities, beginning balance	$1,129		'
Unrealized losses on cash flow hedges, beginning balance	-6,017		'
Total Accumulated Other Comprehensive Loss, beginning balance	-4,888	[1]	'
Unrealized gains (losses) on available-for-sale securities	-1,092		-3
Unrealized gains (losses) on cash flow hedges	795	[2]	4,814	[2]
Total Accumulated Other Comprehensive Loss	-297		4,811
Unrealized gains (losses) on available-for-sale securities, ending balance	37		'
Unrealized losses on cash flow hedges, ending balance	-5,222		'
Total Accumulated Other Comprehensive Loss, ending balance	($5,185)	[3]	'
[1]	Note 1
[2]	Net of tax of $428 and $2,592 for the three months ended March 31, 2014 and 2013, respectively.
[3]	unaudited

Subsequent_Events_Narrative_De

Subsequent Events (Narrative) (Detail) (USD $)	Mar. 31, 2014	Apr. 02, 2014
		Kaleo [Member]
Subsequent Event [Line Items]	'	'
Interest rate of note receivable (in Percent)	'	13.00%
Financing Receivable, Gross	'	$150,000,000
Securitization of notes receivable from first approved product (in percent)	100.00%	'
Securitization of notes receivable from second approved product (in percent)	10.00%	'